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Dissertation Supervised By Dr. Khalid Kamal 
Background: Cystic fibrosis (CF) is a progressive, genetic disorder caused by a mutation 
in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Patients with 
CF experience excessive mucus build up and infections leading to complications in the 
pancreas, lungs, and other organs. There has been a paradigm shift in the treatment of CF 
with the introduction of CFTR modulator therapies and given their high acquisition cost, 
assessing their economic burden along with the adherence rate of patients is imperative.  
Objective: (i) To assess the utilization of CFTR modulator therapies in a specialty 
pharmacy CF patient population and (ii) to calculate the economic burden of CFTR 
modulator therapies and medications utilized for other comorbidities in the CF 
population. 
 v 
Methods: A retrospective data analysis was conducted using refill and patient assessment 
data for CF Patients using CFTR modulator therapies from AllianceRx Walgreens 
specialty pharmacy. The study was conducted in two phases. In Phase I adherence was 
calculated using Proportion of Days Covered (PDC) measurement and data from the 
specialty pharmacy patient assessments focusing on discontinuations, missed doses, and 
medication-related adverse events were extracted and analyzed. In Phase II economic 
burden was assessed by calculating the spending of the specialty pharmacy on CFTR 
modulator therapies, average co-pay of the patients for CFTR modulator therapies and 
the cost of other medications reported by the patients (except CFTR modulator therapies) 
related to symptom management of CF as well as unrelated to CF. All statistical analyses 
were conducted using Statistical Analysis System University Edition (SAS Institute; 
Cary, NC). 
Result: A total of 4,444 patients contributed to 57,960 refills of CFTR modulator 
therapies from January 2015 to August 2018. The overall PDC calculated for the entire 
study period for all CFTR modulator therapies was 0.83. Based on the patient assessment 
data, majority of the patients reported not missing a dose (n=38,428, 93%), switching as 
the most common reason for discontinuing therapy (n=185, 74.9%), and no adverse 
events for all three CFTR modulator therapies (n=23,888, 85-95%). A non-linear trend 
was observed in patient co-pays with a high of $312.70 (2018) and a low of $182.05 
(2016). Patients on primary government insurance had a lower co-pay ($0-$40) compared 
to those on commercial insurance ($20-$310). The annual spending of the specialty 
pharmacy increased from 2015 to 2018 for all three CFTR modulator therapies. The most 
widely reported therapeutic classes for other medications included anti-infectives 
 vi 
(n=2472, 22.81%), respiratory (n=2192, 20.23%), and electrolytes and dietary 
supplements (n=1701, 15.69%). The costs ranged from $0.2-$98,175 for all the other 
medications reported by the patients. 
Conclusion: Patients with CF demonstrated good adherence to CFTR modulator 
therapies.  Additionally, patients reported low missing doses or adverse events, all of 
which could be attributed to the specialty CF pharmacy program. Also, there seems to be 
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CHAPTER 1: BACKGROUND 
INTRODUCTION 
Cystic fibrosis (CF) is a progressive, genetic disease that affects the secretory 
glands, which make mucus and sweat.1 Mucus is also produced by tissues that line 
several organs such as the lungs and nose. The function of mucus is to keep the linings of 
these organs moist and prevent them from drying or getting infected. In CF, the mucus 
becomes thick and sticky and overtime, it can build up in the lungs resulting in blocking 
of the airways and subsequent respiration difficulties. The buildup of mucus in the 
respiratory tract also provides an ideal breeding ground for bacteria and fungi, which can 
lead to repeated, serious lung infections and can cause severe lung damage over time 
(Refer Figure 1).  
In addition to lungs, CF affects other organs such as pancreas, liver, intestines, 
sinuses, and sex organs. In the pancreas, the thick and sticky mucus causes blockage of 
tubes or ducts, which leads to digestive issues as the enzymes produced by pancreas are 
blocked from reaching the small intestine. Due to the lack of enzymes, there is no break 
down and/or absorption of food, resulting in vitamin deficiency and malnutrition. Further, 
patients with CF also suffer from bulky stools, intestinal gas, swollen belly (from severe 
constipation), and pain or discomfort. 
Another disease characteristic is that the sweat of a patient becomes very salty. 
This can lead to an excessive loss of minerals, which upsets the salt and water and causes 
further health complications. These complications include dehydration, increased heart 
rate, fatigue, weakness, decreased blood pressure, heat stroke, and, in rare instances, 
death. It also increases the risk of diabetes, osteoporosis, and osteopenia in patients with  
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Figure 1: Healthy Lung vs CF affected lung 
 





CF. Problems related to reproductive organs are also common amongst patients suffering 
from CF (Refer Figure 2).3 
 
Disease Inheritance  
 
CF is a life-limiting rare genetic disease with autosomal recessive inheritance 
associated with “CF-causing” mutations in the cystic fibrosis transmembrane 
conductance regulator (CFTR) protein. CFTR protein is responsible for regulating the 
flow of salt and fluids in and out of the cells in the body. Mutations in the CFTR gene 
causes the CFTR protein to malfunction or not be produced at all, which results in a 
series of complications in a number of organs including lung infections and destruction of 
the pancreas. 
CF is also classified as a recessive genetic disease which means that that two copies 
of the mutated CFTR gene are necessary to have CF, one inherited from the mother, and 
one from the father. Figure 3 provides a summary of the inheritance pattern of CF. If an 
individual has a mutation in only one copy of the CFTR gene, he or she does not have CF 
and instead is considered a CF carrier. CF carriers can pass their copy of the CFTR gene 
mutation to their children. When two CF carriers have a child together, the chances of a 
child having CF can vary from 25-50%, as discussed below 4,5: 
 25 percent (1 in 4) the child will have CF 
 50 percent (1 in 2) the child will be a carrier but will not have CF 
 25 percent (1 in 4) the child will not be a carrier of the gene and will not have CF 
  
 4 
Figure 2: Organs affected by CF 
 
 




Figure 3: Inheritance pattern of CF 
 
Source: CF Genetics: The Basics 5 
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Individuals with CF can also pass copies of their CFTR gene mutations to their children. 
If someone with CF has a child with a CF carrier, the chances are: 
 50 percent (1 in 2) the child will have CF 
 50 percent (1 in 2) the child will be a carrier but will not have CF 
More than 1,500 CFTR mutations have been identified and over 100 mutations 
have been shown to cause varying degree of disease severity. These mutations have been 
grouped into six classes (Refer Table 1). The five most common mutations that affect 
more than 95% of CF population in the United States (US) are:  
 F508del (86.7% of individuals with CF, Class II mutation),  
 G542X (4.6%, Class I),  
 G551D (4.3%, Class III),  
 R117H (2.7%, Class IV),  
 N1303K (2.5%, Class II).7  
Because not all parents carry identical mutations, a child may therefore, inherit 
different mutations from each parent resulting in differential impact on the CFTR protein. 
This is one of the reasons why a spectrum of the disease phenotypes is observed. 
Additionally, some mutations may only demonstrate a partial effect, which may only 
create a CF phenotype when identified in concert with other specific mutations. This 
complexity coupled with over 1,800 identified mutations in the CFTR gene produces a 





Table 1: Various classes of mutations with their primary defects and the outcomes 
Mutation 
Class 
Defect Outcome  Common 
mutations 
I Protein production Complete absence of CFTR 
protein due to premature 
mRNA terminal (nonsense or 





II Protein processing Inability of protein to localize 
to correct cellular location due 




III Protein regulation Decreased activity of protein 
(chloride channel) in response 
to ATP due to abnormalities of 
the nuclear binding fold regions  
G551D 
IV Protein conduction Frequency of flow of ions and 
channel opening duration are 
reduced though there is 
generation of chloride currents 
on stimulation with cAMP   
R117H 
V Reduced amount 
of functional 
CFTR 
Stability of mRNA and/or 
mature protein is compromised 
A455E 
VI Normal amount of 
functional CFTR 
Enhanced turnover due to C-
terminus abnormalities  
Q1412X 






Unlike other diseases which allow prompt and accurate diagnosis, CF presents 
several diagnostic challenges. However, with the advent of sweat chloride testing and 
more recently, the newborn screening (NBS), accurate diagnosis of CF is becoming more 
practical.  
In 1996, the CF Foundation convened a panel of experts to develop criteria for the 
diagnosis of CF (Refer Figure 4). The panel’s consensus was that the diagnosis of CF 
should be based on the presence of one or more characteristic clinical features, a history 
of CF in sibling, or a positive NBS test including laboratory evidence of an abnormality 
in the CFTR gene or protein. Acceptable laboratory evidence of a CFTR abnormality 
included biological evidence of channel dysfunction (i.e., abnormal sweat chloride 
concentration or nasal potential difference) or identification of a CF disease-causing 
mutation in each copy of the CFTR gene. The evidence of CFTR abnormality is 
necessary since the NBS test is just a screening that identifies individuals at risk for CF. 
Positive NBS should be followed by a sweat chloride test to confirm a CF diagnosis.9,10 
NBS for CF is usually done in the first few days after birth as early diagnosis of CF helps 
in the prevention of serious lifelong health problems. In NBS, a blood test is conducted to 
check the levels of a chemical made by the pancreas called immunoreactive trypsinogen 
(IRT). Usually, IRT levels are low in individuals without CF. However, individuals with 
CF tend to have high (> 55 ng/mL) IRT levels. Because IRT levels can also be high in 
premature birth, stressful delivery, or due to other reasons, DNA test is utilized to check 
for mutations or changes in the CF gene. Even with the DNA test, NBS is only a 
screening tool and for an actual diagnosis, a sweat test, considered the gold standard for  
 9 
Figure 4: CF Foundation recommended diagnostic process for screening newborns 
 
Source: Farrell et al., 2016 10 
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confirming the diagnosis, must be performed.11 This test measures the amount of chloride 
(a component of salt) in the sweat since individuals with CF have more chloride in their 
sweat than those without CF. If a sweat test is done correctly, then results that are 
positive will show a high chloride level. A chloride level of less than or equal to 29 
mmol/L signifies that CF is unlikely regardless of age. Repeated testing is needed when 
individuals have chloride levels between 30 - 59 mmol/L and those with chloride levels 
greater than or equal to 60 mmol/L are likely to be diagnosed with CF. Appropriate sweat 
chloride testing is crucial for the diagnosis of CF and CF Foundation  requires the testing 
to be conducted at accredited CF centers.12  
 
SYMPTOMS OF CF 
The symptoms of CF and symptom severity vary from individual to individual. 
Some children may start showing symptoms at birth while some may not show symptoms 
for weeks, months or even years. The symptoms are broadly categorized into symptoms 
of the respiratory tract and other symptoms.  
Symptoms of the respiratory tract:13  
 Chronic coughing (dry or coughing up mucus) 
 Recurring chest colds 
 Wheezing (that may not respond to standard asthma therapy) 
 Shortness of breath 
 Frequent sinus infections 
 Allergies that last all year 
 Recurrent lung infections 
 11 
Other symptoms:14 
 Frequent large, greasy, and foul-smelling bowel movements 
 Inability to gain weight despite being hungry all of the time 
 Poor growth 
 Constipation and intestinal blockage 
 Recurrent inflammation of the pancreas (pancreatitis) 
 Symptoms of high blood sugar, such as being thirsty and urinating frequently 
 Gallstones 
 Excessive sweating 
 Salty-tasting skin 
 
TREATMENT OF CF 
Currently, there is no cure available for CF and most treatments generally aid in 
reducing symptoms and CF-related complications. The management of CF is complicated 
as it involves the treatment of a myriad of symptoms. Normally, a multidisciplinary team 
of healthcare professionals deliver treatments to keep the lungs clear, prevent or fight 
infections, and provide adequate nutrition.  
Airway clearance technique 
Airway clearance techniques (ACTs) loosen thick, sticky mucus so it can be 
cleared from the lungs by coughing or huffing. Clearing the airways may help in 
decreasing lung infections and improving lung function. This can be done using manual 
chest physiotherapy or a device called the Vest. This jacket shakes the mucus in the 
airways, enabling the patient to cough it up. Another portable device is called a "flutter." 
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This causes the mucus in the airways to vibrate or "flutter" when a patient breathes 
through the device.15,16 
Medications 
 Antibiotics 
The buildup of thick, sticky mucus in the lungs makes individuals with CF more 
susceptible to bacterial infections that can last for short periods of time (acute infections 
or exacerbations) or for many years. Antibiotics are recommended to be taken regularly 
by patients to keep these infections in check. In serious cases, individuals with CF may 
receive intravenous (IV) antibiotics in addition to inhaled or oral antibiotics. Some 
examples of these drugs include ciprofloxacin, tobramycin, cephalexin, azithromycin, 
and amoxicillin. 17,18 
 Anti-inflammatory agents 
Inflammation plays a major role in the pathophysiology of lung disease in CF. This 
response is primarily triggered as a reaction to the inability of the affected lung to resist 
the invasion of the common bacterial pathogens commonly seen in CF. Various anti-
inflammatory treatment modalities have been tested to be used in CF. Oral corticosteroids 
are effective but associated with significant long-term side effects whereas inhaled 
corticosteroids are so far not proven to be effective mostly due to the difficulty with their 
absorption through the viscid surface secretions of the lung. Also, ibuprofen is potentially 
effective but limited because of the need to monitor drug levels and due to its 
potential gastrointestinal side effects. Currently, the most promising agents are macrolide 
antibiotics such as azithromycin, which possess long-term anti-inflammatory effect and 
an excellent safety profile.18,19 
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 Bronchodilators 
Bronchodilators widen the airways by helping the surrounding muscles to relax. This 
allows more air to travel through the airways, which ultimately help other medications to 
work more effectively. Bronchodilators can be taken before other treatments such as 
mucus thinners, airway clearance techniques and antibiotics. Some commonly used 
bronchodilators include albuterol and levalbuterol hydrochloride, which can be 
administered using metered dose inhaler, nebulizers or dry powder inhalers.20 
 Mucus thinners 
Because the primary physiologic manifestation of CF in the lungs is defective 
mucociliary clearance, it is only logical that several therapies have been developed to 
target this defect. To maintain healthy lungs, airway secretions need to be mobilized to 
not only relieve airway obstruction but also reduce infection and airway inflammation. 
Effective airway clearance techniques are essential components of CF therapy, hence 
mucus thinners such as dornase alfa and hypertonic saline are incorporated in the therapy. 
Aerosolized mucolytic agents have been incorporated into CF care to clear airway 
secretions. Dornase alfa cleaves the DNA released in high concentrations by degraded 
neutrophils present in CF mucus, thus reducing sputum viscosity and leading to slower 
lung function decline and fewer pulmonary exacerbations. Inhaled hypertonic saline leads 
to a temporary increase in mucociliary clearance by increasing the depth of the periciliary 
fluid space and lowering mucus osmolality. This has been widely adopted in children and 




 Enzyme therapies 
Just as the lungs produce thick, sticky mucus, the pancreas also makes thick mucus 
that blocks the release of enzymes needed for digestion. Most people with  
CF need to take enzymes before they eat. Enzymes such as creon, pancreaze, etc. work 
by helping a patient digest carbohydrates, proteins and fats, gain and maintain a healthy 
weight along with absorbing essential nutrients such as vitamins and minerals. 22 
 CFTR Modulators 
Historically, treatment of CF has focused on the downstream effects of CFTR 
dysfunction, which includes impaired mucociliary clearance, chronic infection, and 
chronic inflammation. The ideal therapy for CF lung disease would be to directly treat the 
disease proximate to the gene or protein defect, allowing for normal or near-normal 
CFTR function. Despite its early promise, gene therapy has yet to be successful in 
patients with CF. One of the most exciting advances in CF therapeutics is the discovery 
of small molecules that alter mutant CFTR function called the CFTR modulator 
therapies. These are designed to correct the malfunctioning protein made by the CFTR 
gene. They act by improving production, intracellular processing, and/or function of the 
defective CFTR protein. Because different mutations cause different defects in the 
protein, the medications that have been developed so far are effective only in individuals 
with specific mutations. There are three approved CFTR modulators: ivacaftor 






Incidence and Prevalence of CF  
In 2017, around 30,000 individuals in the US and more than 70,000 worldwide were 
reported to have CF (Refer Figure 5). Additionally, 1,000 new cases are diagnosed each 
year and more than 75% of individuals with CF are diagnosed by the age of 2. CF is one 
of the most common genetic diseases in Caucasians, occurring in 1 in 2,500 to 3,500 
newborns. It is less common in other ethnic groups, affecting about 1 in 17,000 African 
Americans and 1 in 31,000 Asian Americans. Worldwide, the incidence of CF is as high 
as 1:377 in parts of England and as low as 1:90,000 among Asians in Hawaii. In Europe, 
the rate of CF is between 1:2000 and 1:3000 births. In Southern Africa, the carrier 
frequency is 1:42, with a calculated incidence of 1 in 7,056 births. The incidence in Latin 
America ranges from 1:3900 to 1:8500. Estimates for the Middle East region are between 
1:2560 and 1:15,876 whereas CF is rare among Asians. In India, the prevalence is 
estimated at around 1:40,000 to 1:100,000 births. In Japan, the estimated incidence is 
1:100,000 to 1:350,000. 24,25 
Outcomes and survival rates for CF have improved drastically over the past 50 years. 
Once an exclusively pediatric illness due to early mortality, individuals with CF are now 
surviving commonly into adult life. The median age of patients with CF in the US is 19.3 
years but some patients are as old as 87 years. Worldwide, the median survival rate varies 
from country to country; and is still the highest in the US. An individual born in the US 
today is expected to survive beyond 40 years of age. With current treatment strategies, 
80% of the patients most likely reach adulthood. Nevertheless, CF remains a life-limiting 
disease and a cure for the disease remains elusive.  
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Figure 5: Prevalence of CF from 1987-2017 
 
Source: CF Foundation Registry Report, 2017 24  
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ECONOMIC IMPACT OF CF MEDICATIONS 
The mean expenditures for CF (after adjusting for inflation) doubled from 
$67,000 per patient in 2010-11 to $131,000 in 2016. 26A major contributor to this 
increase was the growth in pharmaceutical spending whose share in the total spending 
increased from 35.8% in 2010 to 64.1% in 2016. The growth in pharmaceutical spending 
can be attributed to the introduction of specialty drugs, including the CFTR modulator 
therapies. The annual wholesale acquisition costs (WAC) reported for Kalydeco® 
(ivacaftor) introduced in 2012, Orkambi® (ivacaftor/lumacaftor) in 2015 and Symdeko® 
in 2018 (ivacaftor/tezacaftor) are $272,886, $311,719 and $292,258, respectively. It was 
observed that in patients who took ivacaftor and ivacaftor/lumacaftor, the drugs 
accounted for 85% and 74% of their total pharmaceutical spending, respectively. 26,27 
A 2018 report by the Institute for Clinical and Economic Review aimed to 
evaluate the long-term cost effectiveness of CFTR modulator therapies. The report 
concluded that all drugs (plus best supportive care) were very effective compared to best 
supportive care alone in all populations studied, with the quality-adjusted life years 
(QALYs) gains ranging from 5.47 to 6.73. Also, the CFTR drug-related costs ranged 
from $4.9 million to $7.4 million with the incremental cost-effectiveness ratios of drugs 
plus best supportive care compared to best supportive care alone being approximately 
$0.9 million per QALY for all drugs in all population. Hence, at the current cost, the 
CFTR modulator therapies are way over the acceptable cost-effective threshold of 
$50,000-$100,000/QALY . 27 
Along with CFTR modulator therapies, other specialty drugs (both pulmonary and 
pancreatic therapies) have shown an annual growth of 17.1-17.3% and 9.1-9.2%, 
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respectively. The increasing costs of CF medication are a huge concern to the patients 
and their caregivers. Even though most patients have health insurance coverage, the 
uncertainty about future insurance coverage for these expensive treatments is a constant 
cause of worry.  
 
MEDICATION ADHERENCE 
Medication adherence is defined as “the degree to which the person’s behavior 
corresponds with the agreed recommendations from a health care provider."28 It usually 
refers to whether patients take their medications as prescribed (e.g., twice daily), as well 
as whether they continue to take a prescribed medication. Medication nonadherence 
could be either intentional due to side effects, financial reasons etc. or non-intentional 
like forgetting to take the medication. Medication nonadherence is a growing concern to 
clinicians and other healthcare stakeholders because of mounting evidence that 
nonadherence is associated with adverse clinical outcomes leading to higher healthcare 
utilization. 
 Medication adherence can be assessed using direct and indirect methods.29 Direct 
methods include measuring the level of medicine or metabolite in the blood or any other 
biological marker. Indirect methods include patient self-report, pill counts and pharmacy 
refills. Although the direct methods are robust than indirect methods, they are not 
practical for routine clinical use. As electronic pharmacy data are becoming available, 
they are being frequently utilized for calculating medication adherence. The act of 
obtaining refills and the frequency at which they are acquired depict different aspects of a 
person’s adherence behavior.29 Currently, the two measures of adherence based on the 
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pharmacy data reported in the literature include medication possession ratio (MPR) and 
proportion of days covered (PDC). The formula to calculate these measures is as follows: 
 MPR= (Sum of days’ supply for all fills in the period/ Number of days in period)  
 PDC= (Number of days in period “covered”/Number of days in period)  
 The major difference between the two measurements is that the maximum value 
of PDC is 1.0 which indicates full adherence whereas MPR takes oversupplies into 
consideration and can have a value of greater than 1.0.  
 Patients with CF and their caregivers face constant challenge of fitting complex 
treatment routines into their daily schedule. It has been estimated that these routines 
consume nearly 2 hours every day out of their schedule that is already covered with 
school family, work and other commitments. Adherence to CF care plans is critical as 
nonadherence is linked to poor health outcomes resulting in longer hospital stays, higher 
respiratory exacerbation cost, increased hospitalizations, increased number of pulmonary 
exacerbations requiring intravenous antibiotics, and lower baseline lung function.30,31 
A study assessing the association of adherence to pulmonary medications to lung 
health outcomes in CF population reported that group with the lowest adherence (<50%) 
had the highest probability of having an exacerbation.32 Another study reported an 
association of lower adherence to dornase alpha to longer lengths of hospital stay and 
higher costs of pulmonary exacerbations.33 Research indicates that lower adherence to 
medications maybe in part due to difficulties with time management, forgetfulness, 
increased regimen complexity, decreased parental supervision in adolescents, perceived 
doubts about the necessity of treatments, stigma and reluctance to disclose CF status, and 
depression in both patients and their caregivers.34    
 20 
Also, most patients with CF reported that added time burden in working with their 
insurance payers and pharmacies to obtain the appropriate prior authorizations and 
approvals for the specialized medications as a barrier to care. Cost containment efforts by 
payers including restricting these medications in their formulary presents additional 
burden for patients and providers. There is a need to develop policies to streamline this 
process so as to help individuals obtain their medications on a routine basis and assist 
with being adherent to their medications.31 
 
PROBLEM STATEMENT 
 CF is a complex disease that requires a patient to take a number of medications on 
a daily basis to avoid disease-related complications. Even with the consumption of 
numerous medications, generally the disease symptoms are controlled. However, with the 
introduction of CFTR modulator therapies, patients (with specific mutations) have an 
opportunity to slow the disease progression. As these expensive medications are orally 
administered, there is a need to assess their adherence. Currently, there is a dearth of 
studies reporting the adherence rates of CFTR modulator therapies. Given their high 
acquisition cost, assessing their adherence rate is warranted. 
In recent times, a lot of focus has been placed on the increasing costs for the CF 
treatments. Few studies have assessed the overall medication costs in CF population but 
only one study was conducted after the introduction of CFTR modulator therapies. Also, 
this study did not assess the cost of medications specifically prescribed for co-
morbidities. Given the high burden of comorbidities in CF population, the cost of 
medications for other co-morbidities can be substantial. Thus, there is a need to evaluate 
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This study will utilize real-world data from AllianceRx Walgreens Prime 
Specialty Pharmacy, which provides CF management program, reimbursement support 
and patient advocacy to its patients. Pharmacy dispensing records and self- reported 
patient assessment data will be analyzed to provide an overview of the utilization pattern 
of CFTR modulator therapies. This study will involve all the patients who had a 
minimum of one dispensing record of a CFTR modulator therapy at AllianceRx 
Walgreens Prime Specialty Pharmacy from January 2015 to August 2018.  
 
Part I 
In the AllianceRx Walgreens Prime Specialty Pharmacy database, every patient is 
assigned a unique Patient ID. This Patient ID is linked to their CFTR dispensing 
information, which was utilized to calculate PDC, as an adherence measurement. 
Furthermore, AllianceRx Walgreens Prime Specialty Pharmacy routinely collects patient 
data regarding switching, forgetting and discontinuing of therapies. This self-reported 
data was analyzed to describe the problems associated with CFTR modulator therapies. 
 
Part II  
As the CFTR modulator therapies are extremely expensive, there can be a 
substantial cost to the patient as a part of the copay even though the medications may be 
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covered by the health insurance plans. Therefore, the study will calculate the average co-
pay associated with each CFTR modulator therapy depending on the insurance status of 
the patient. AllianceRx Walgreens Prime Specialty Pharmacy also collects information 
regarding the comedications of patients, which will be used to understand the economic 
burden of these medications in CF. 
 
STUDY HYPOTHESIS 
The hypothesis for the first part of the study is that the adherence rate of patients 
to CFTR modulator therapies will be high given the nature of the disease. The hypothesis 
for the second part is that there is a substantial economic burden associated with co-pay 
on the patient with CF for CFTR medications and cost of comedications. 
 
STUDY SIGNIFICANCE 
The adherence to CFTR modulator therapies is important in order to slow the 
disease progression and avoid further complications. Since adherence has not been 
reported in the literature, this study will the first to assess the adherence rates of these 
medications in CF. Using the specialty pharmacy data for CFTR modulator therapies, the 
study will also provide useful data on the real-world trends in CF.  
While adherence rate calculations are important, analyzing the reported reasons 
for missing doses or discontinuing therapies is also important as it will help us understand 
the motives behind lower adherence rates. This can potentially assist providers in creating 
interventions that can improve adherence, which in the long run can reduce the healthcare 
spending. Similarly, assessing the relationship between adherence and payer 
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characteristics (if any) will highlight the importance of secondary payer. This information 
can be utilized by specialty pharmacies in guiding their patients to choose the right 
payment plan for their treatment.  
With the emphasis on the cost of CFTR modulator therapies, only a handful of 
studies have assessed the cost of other medications in the treatment of CF. Along with the 
symptoms of CF, patients suffer from additional co-morbidities resulting in substantial 
treatment costs.  Hence, this study will be among the few to assess the economic burden 
of comedications in CF. This will include the cost of medications related to symptom 
management of CF as well as unrelated to CF. This information will help all the 
stakeholders involved in CF care to understand the medication spending patterns. This 
has implications for future resource allocation decisions. 
 
STUDY OBJECTIVES AND RESEARCH QUESTIONS 
The study objectives and specific research questions are as follows: 
Part I: Utilization of CFTR modulator therapies  
To assess the utilization of CFTR modulator therapies in a specialty pharmacy CF patient 
population 
Research Questions: 
1. To describe the demographics, medication utilization, and insurance characteristics 
for patients on CFTR modulator therapies 
2. To identify reasons for missed doses, medication discontinuation, and CFTR 
modulator therapy-related adverse events  
3. To calculate medication adherence rate using PDC as a measure for patients with 
more than one refill for CFTR modulator therapies and explore the association 
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between medication adherence rate and payer characteristics (those with and without 
secondary insurance) 
 
Part II: Economic burden of CFTR modulator therapies and co-medications 
To calculate the economic burden of CFTR modulator therapies and medications utilized 
for other comorbidities in the CF population. 
Research Questions: 
1. To analyze the spending pattern of the specialty pharmacy on CFTR modulator 
therapies from 2015-2018 
2. To identify the average co-pay of patients for CFTR modulator therapies based on 
payer type 






CHAPTER 2: SYSTEMATIC LITERATURE 
REVIEW 
The economic burden related to CF treatment has increased considerably over the 
last decade, especially with the introduction of CFTR modulator therapies. Thus, the total 
treatment costs of CF in the US and globally needs to be examined. This chapter reports 
the findings of a systematic literature review conducted to estimate the economic burden 
of CF. 
METHODS  
Following the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guideline, a systematic literature review was conducted to identify 
published literature from January 2008 till December 2018. The search strategy was 
developed using keywords related to CF and economic burden (Refer Table 2). The 
search strategy was then executed in PubMed and Scopus databases (Refer Appendix I). 
Articles identified in the search were screened for duplicates following which their title 
and abstracts were reviewed against inclusion/exclusion criteria and relevancy to study 
objectives. Further, the articles underwent full text review and those that met the study 
objectives were included in the final review. 
Inclusion/Exclusion Criteria 
English-language articles which quantified the burden of CF using real world cost 
data in monetary units were included in this review. Articles which estimated the burden 
of diseases using economic models were excluded from the study along with review  
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Table 2: Keywords used in the search strategy 
 
Keywords related to 
CF 
Keywords related to economic burden 
Cystic Fibrosis, 
Mucoviscidosis 
Economics, cost of illness, cost of disease, cost of sickness, 
healthcare costs, healthcare expenditure, healthcare 
utilization, direct service costs, hospital cost, 
hospitalization cost, drug cost, economic burden, economic 
impact, economic cost, economic analyses, economic 




articles, theses/dissertations, conference abstracts, commentaries, editorials, and 
systematic reviews. 
RESULTS 
The search strategy identified a total of 1,285 articles from PubMed and Scopus. 
After removing 261 duplicates, 1,024 articles were screened against the 
inclusion/exclusion criteria and 30 were included in this review (Refer Figure 6). The 
studies were conducted in 13 countries covering three regions including Europe (n=16, 
53%), North America (n=12, 40%) and Australia (n=2, 7%). The methodology of the 
studies varied from primary data collection in patients and/or physicians to secondary 
data analyses. All the studies estimated the direct medical costs of CF while a few (n=6, 
20%) quantified the CF-related indirect costs.  
In international studies, the major direct medical costs included hospitalization 
costs, physician visits, medication use and pathology tests. A number of studies (n=6, 
37.5%) concluded that as a single cost item, medications were the major cost drivers of 
CF-related direct costs. Mlcoch et al. estimated that out of the total direct medical costs 
of €14,486 (2018- $18,474.26) per patient in the Czech Republic, €10,321(2018-
$13,162.55) was spent on medications.35 Huot et al. estimated that medications accounted 
for 45% of the total CF-related direct medical costs per patient in France while 
Heimeshoff et al. estimated that 76% of total (direct and indirect) costs were due to high 
drugs costs per patient in Germany. 36,37  Angelis et al. reported that the direct non-
medical costs were the largest component (44.3%) of the total average costs per patient in 
the United Kingdom (UK). 38 Within the direct non-medical cost category, informal care 
had the biggest share averaging €21,447 (2018- $28,362.88), accounting for 99.6% of the  
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Figure 6: Schematic representation of the systematic literature review 
 
 
Reference: Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The 
PRISMA Statement 39   
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direct non-medical costs and 44.1% of total costs. Informal care was operationalized as 
the time spent by non-professional caregivers helping the patient with their basic 
activities of daily living. 38 
While international studies estimated all the cost components of CF, the US-based 
studies assessed only the direct medical costs related to the disease. Hospitalizations, 
outpatient visits and pharmacy costs were the most frequent resources captured in the US 
studies. Briesacher et al. observed that the per person costs for CF increased by 61% 
from 2001 to 2007 while the prescription drug costs increased by 66% during the same 
time period. 40 Similarly, Grosse et al.  reported that the expenditure in commercially 
insured individuals with CF doubled from 2010 to 2016 but the total spending on 
pharmaceuticals increased from 35.8% to 64.1% in 2016. 26  
Although all of these studies have utilized various resources to calculate the 
economic burden associated with CF, only two of them have included the cost of CFTR 
modulator therapies. Corcoran et al. calculated the drug acquisition cost for ivacaftor at 
€29.81 million (2018- $37.01 million) for a total of 140 people in Ireland. 41 Similarly, 
Grosse et al. observed that in 5.8% of CF patients who took ivacaftor in 2016 in the US, 
the drug accounted for 85% of their pharmaceutical spending and lumacaftor/ivacaftor 
taken by 17.6% of the CF population accounted for 74% of their total pharmaceutical 
spending.26 Overall, there seems to be an increase in the cost of CF treatment which 
could be attributed to the introduction and increase in the utilization of CFTR modulator 
therapies along with the inflation over the years. 




















To analyze the High-Tech Drug 
Scheme pharmacy claims database 
over a 12-month period (from 
January 2015 to December 2015 
inclusive) to examine the number of 
individuals who had been prescribed 










 The cumulative drug acquisition 
expenditure on Ivacaftor over the 
12-month study period was 
€29.81 million for a total of 140 
individuals 
Jackson et 





To examine the direct medical cost 
borne by the health service in 
providing healthcare resources and 


















 The median annual total cost per 
patient increased over the period 
2008–2012 from €12,659 to 
€16,852 
 Inpatient bed-day cost increased 
from €14,026 to €17,332 
 Medication cost increased from 
€5,863 to €12,467 
 Homozygous F508-CFTR 
mutation (class II) cost was 
highest and milder mutation 
(class IV/V) cost was 49% lower. 
Kopciuch et 





To understand the regimen of 
pharmacotherapy in adult CF 
population in Poland, and to 
calculate the costs of drugs used in 
this group of patients. 
Data from a 
CF hospital 
clinic 
Medication costs 2013, 
Euro 
 Total pharmacotherapy cost in 
2013 amounted to €467,876.66 
giving €10,171.23 (± 2818.39) 
per patient.  
 The most popular group of drugs 
used by CF patients was 
mucolytic drugs, with the 
estimated cost of €382,054.21.  
Kopciuch et 





To calculate costs associated with CF 
treatment in Poland as well as at 
comparison of average costs of 
treatment of CF patients in selected 
countries, taking into account the 
purchasing power parity. 







diagnostic tests and 
transportation 
Indirect Costs:  
2013, 
Euro 
 Total annual treatment cost per 
one CF patient in Poland was on 
average €19,581.08. 
 Total direct costs amounted to 
€634,714.37 (on average: 






Presenteeism   Direct costs made up the largest 
share of total costs, and direct 
medical costs made up as much 
as 70% of total costs. 
Mlcoch et 






To retrospectively assess CF health 
care costs within a representative 
cohort of Czech patients drawn from 
















 The mean total health care costs 
were €14,486 per patient, with 
the majority of the costs going 
towards medicinal products and 
devices (€10,321).  
 Medical procedures (€2676) and 
inpatient care (€1829) 
represented a much smaller 
percentage of costs. 
Chevreul et 











To estimate the social/ economic 
costs considering three dimensions—
direct healthcare costs, direct non-
healthcare costs (formal and informal 
care), and labor productivity losses—
and to assess Health related quality 
of life (HRQoL) in patients with CF 




















(provided either at 
home by a 
professional 
caregiver or in 
institutions run by 
social services) and 
non-healthcare 
transport 




 The total mean cost of CF varied 
from €21,144 in Bulgaria to 
€53,256 in Germany.  
 Healthcare costs ranged from 
€12,161 (Bulgaria) to €28,827 
(Germany).  
 The main items were 
hospitalizations and drugs. 
 Non-healthcare costs ranged 
from €6,313 (Hungary) to 
€21,528 (UK), with informal 
care being the highest cost item.  
 Labor productivity losses ranged 
from €1,094 (Bulgaria) to 
€12,443 (UK). 
 Adults had higher direct 
healthcare costs than children, 
but children had much higher 
informal care costs.  
 Total costs increased with 
patients’ level of dependence. 
Angelis et 
al, 38  
 
2015 
To estimate the societal costs of CF 
by accounting for all direct health, 











 Estimated average annual cost 
per patient in 2012 was €48,603, 








costs, and, second, to assess the 
HRQoL of patients with CF. 
sampling from 
CF trust 




















 Direct non-health care cost was 
the largest component (44.3 % of 
the total average cost per 
patient), followed by direct 
health care costs (42.9 %) and 
productivity loss (12.8 %).  
 On average, the largest 
expenditures by far were 
accounted for by informal care 
(44.1 %), followed by 
medications (14.5 %), acute 
hospitalizations (13.9 %), early 
retirement (9.1 %) and outpatient 
and primary health care visits 







To provide data on the economic 
burden and HRQoL associated with 




























 The total average annual cost of 
CF was €29,746 per patient.  
 Direct healthcare costs accounted 
for over half, with drugs and 
hospitalizations representing the 
largest shares.  
 Direct non-healthcare formal 
costs were estimated at €4,512, 
with social services accounting 
for 92.6% of that cost. 
 Direct non-healthcare informal 








retirement (patients)   





To identify potential predictors of 
resource use in the management of 
CF, and examine how these 














 The mean and median costs were 
A$33,563 and A$23,685 






To estimate the social economic 
costs in a triple dimension of direct 
health care costs, direct non-health 
care costs (formal and informal care) 
and labor productivity losses, as well 
as to assess the health-related quality 
of life (HRQoL) of Bulgarian CF 


























 Median annual costs of CF in 
Bulgaria were €24,152 per 
patient.  
 Median annual costs for children 
were found to be significantly 
higher than those for adults – 
€31,945 vs. €15,714.  
 As a single cost item, drugs had 
the biggest monetary impact. 
Median annual drug costs were 
€13,059 
Colombo et 





To estimate the mean annual costs 
associated with the treatment of CF 
patients for the Italian National 
Healthcare Service  
Collected 
through a 
sample of CF 
patients  
Direct medical 
costs- drug costs, 
hospitalization costs 






 The mean annual cost/patient 
increased with age and lung 
disease severity from €4,164 in 
children aged ≤5 years to 
€30,123 in patients aged >5 years 












To estimate the rate of CF 
progression for various age groups 
and health states as well as the health 
care costs associated with treating CF 
Australian CF 
Data Registry  





number of clinical 
visits, use of oxygen 




 The mean annual cost associated 
with CF management is US 
$15,571, with a 95% confidence 
interval range of US $15,032 to 
US $16,110. 
Heimeshof 





To calculate the average total costs 
of CF per patient and per year from a 
societal perspective; to include all 
direct medical and non-medical costs 
as well as indirect costs; to identify 
the main cost drivers; to investigate 
whether patients with CF can be 
grouped into homogenous cost 
groups according to defined severity 
levels; and to determine the influence 





costs: Drug costs, 
laboratory costs, 
staff costs for 





Indirect costs: Costs 
of absence from 
work and 
productivity losses 
due to CF. 
2004, 
Euro 
 The mean total cost per patient 
per year was €41,468.  
 Direct medical costs (inpatient 
and outpatient care including 
outpatient drugs) averaged 
€38,869 per patient per year and 
accounted for 94% of total costs.  
 Indirect costs amounted to 
€2,491 (6% of total costs). 
 Costs for drugs patients received 
at the outpatient pharmacy were 
the main cost driver.  
 Costs rose with the degree of 
severity. Patients with moderate 
and severe disease had 
significantly higher direct costs 
than the relatively milder group. 
Eidt-Koch 





Detailed evaluation of direct costs in 
outpatient treatment of CF patients in 
Germany measured by valuing the 
actual consumption of resources and 
a comparison of these costs with the 
current reimbursement situation 

















dietician, etc.,  
2006, 
Euro 
 Costs due to the resources used 
in the clinic add up to mean of 













To identify per patient average 
resource use and costs for personnel 
at a CF outpatient center from the 
health care provider’s perspective; to 
assess whether outpatients can be 
grouped into cost homogenous 
clusters of patients according to sex, 
age group, and disease severity 
levels; and to evaluate the value of 
demographic and clinical variables in 





Staff costs 2004, 
Euro 
 The mean total staff costs per 
patient amounted to €142.3 over 
six months of outpatient service, 
ranging from €22.1 to €669. 
Eidt-Koch 





To analyze in detail the costs of 
outpatient medication for CF patients 







units based at 
university 
hospitals 
Medication costs 2006, 
Euro 
 The total daily medication cost 
for all 301 patients was €17,815, 
resulting in mean daily 
medication costs in outpatient 
treatment of €59.19 per patient. 
 An extrapolation to 1 year of 
treatment yielded total outpatient 
medication costs of €6,502,791 
for the 301 study patients, with 
average costs of €21,603 per 
patient per year 
Braccini et 





The aims of the study were to: define 
the costs of antibiotic treatment of 
Tuscan CF patients with P. 
aeruginosa infection treated 
according to the Consensus statement 
6; to describe the differences in cost 
of antibiotic treatment in patients 
with first or new P. aeruginosa 
infection compared to those with 
chronic infection; and to analyze the 




Prescription costs 2006, 
Euro 
 Total costs over the period 2002-
2006 amounted to €384,207.00 
with a mean cost per patient of 
€6,298.00 (€1,259.00 per patient 
per year) for early eradication 
treatment. 
 85.7% of the costs of antibiotic 
treatment (€2,303,852.00) were 
for treatment of patients 
chronically infected by P. 






and cost of antibiotic treatment for 
outpatients and inpatients. 
costs (€384,207.00) were for 
treatment of inpatients who had 
undergone early antibiotic 
treatment. year) for early 
eradication treatment.  
 Of the €2,303,852.00 overall cost 
of antibiotic treatment for 
chronically infected patients, 
€2,125,733.00 (95%) were for 
outpatients and €115,119.00 
(5%) for inpatients.  





To evaluate the trends in CF related 
costs following the advances in CF 























 Average cost of CF was 
€16,474/patient/year in 2000, 
and €22,725 in 2003. 
 Hospital care increased from 
15% of the total cost in 2000 to 
22% in 2003. 
 Medications accounted for 45% 
of the total cost for the two 
periods, with an average cost of 
€7229/patient/year in 2000 and 
€10,336 in 2003.  
 Home intravenous antibiotic 
therapy accounted for 20% of the 
total cost for the two periods. 






















To describe current 
trends in health care 
expenditures for 
commercially insured 
patients with CF in the 
US. 







of claims data) 
Inpatient services  
Outpatient services- 
outpatient encounters, 
emergency room (with 
discharge home), 






2016, USD  Median expenditures increased 
from $32,586 in 2010 to $67,760 
in 2016, more than doubling in a 
period of 5 years.  
 The share of pharmaceuticals in 
total spending increased from 
35.8% in 2010 to 64.1% in 2016.  
 The annual growth rate in 
pharmaceutical spending rose by 
33.1% during 2014-2016, the 
years during which 
lumacaftor/ivacaftor was 
introduced. 






To describe the overall 
burden of CF in this 
population, particularly 
in terms of the incidence 
of Pulmonary 
exacerbations (PEx) 
episodes and their 
associated costs as well 
as Inpatient admissions, 
antibiotic use, and 
overall health care 
resource utilization. 
Medical and 
pharmacy claims data 




Inpatient, Outpatient and 
Pharmacy costs 
described over a year as 
well as during each 
pulmonary exacerbation 
event 
2014, USD  Mean (SD) health care costs 
during a PEx event were 
US$75,623 (US$205,236), 
driven by Inpatient costs of 
US$58,468 (US$197,046), and 
followed by Outpatient costs 
(US$2882 [US$7430]), office 
visits (US$233 [US$314]), and 
ER visits (US$169 [US$670]) 
 Mean (SD) pharmacy costs were 
US$14,273 (US$21,415) and 
mean (SD) antibiotic costs were 
US$5716 (US$10,555). 
 Among mean (SD) antibiotic 
costs, inhaled was highest at 
US$3934 (US$7961), followed 
by oral at US$1270 (US$4293), 













To determine patient, 
hospital, and clinical 
characteristics associated 
with the length of stay, 
total hospital charges, 





Sample data collected 
by Healthcare Cost 
and Utilization 
Project (HCUP) 
Hospital charges and 
hospital costs 
2012, USD  Among children, the mean 
hospital costs were $26,249.23 
(40,592.81). 
 Adults had mean hospital costs 
of $21,600.91 (31,997.52) 
 Total hospital charges were 
higher in patients covered under 
Medicare and hospitals with a 
small bed size while total 
hospital costs were higher in 
people without any insurance 
and hospitals with a medium bed 
size. 
Agrawal et 





To assess recent changes 
in the frequency and cost 
of inpatient admissions 
for a principal diagnosis 
of CF patients in the US 
from 2003 to 2013 
National Inpatient 
Sample from HCUP 
Hospital Charges 2003 to 
2013, USD  
 The aggregate cost of hospital 
visits of patients with the 
principal diagnosis of CF 
increased 138.31% from US 
$500,105,727 in 2003 to US 
$1,191,819,760 in 2013. 






To examine the burden 
of PEx and associated 
costs among a national 
sample of pediatric and 
adult patients with CF 
with commercial 
coverage from a large 
US health insurer 
affiliated with Optum 
from 2008 to 2013 
Administrative 
claims data from a 
large, US health 
insurer with national 
coverage 
Cost associated with 
pulmonary exacerbation 
event 
2013, USD  The mean cost per episode was 
$12,784 for PEx of any type and 
$36,319 for inpatient stay 
 Mean (median) annual costs 
attributable to PEx of any type 
were $37,025 ($10,833) among 
all patients and rose with stage 
of lung disease from $30,066 
($9456) among patients with 
mild disease to $119,862 
($48,263) among patients with 
severe disease 




To estimate the cost of 
care for a unique cohort 
of children with CF 
followed over time from 




Outpatient costs and 
drug costs 
2010, USD  Seventy-three children were 
followed for an average of 12.9 
years with an average annual 








infancy, and separately 
identify cost of care by 
different disease risk 
factors known at birth. 
 Outpatient drug costs (53%) and 
hospitalizations (32%) 
represented the majority of costs.  
 The average annual drug costs 
were $13,068 with $6,292 (48%) 
representing pulmonary drugs. 










medical outcomes, and 
healthcare utilization 
with the goals of 
identifying the impact of 
mental health issues on 
health outcomes and 




outpatient clinic visits 
USD  Hospital-based charges for the 
depressed group were on average 
more than four times higher than 
those for the non-depressed 
group (means of $280,000 and 
$60,116, respectively) 
Sansgiry et 





To describe the 
P.aeruginosa infection-
associated healthcare 
utilization and costs 
across the spectrum of 
care among CF patients 





database for 2005– 
2008 
Inpatient care: visits, 
hospital length of stay 
Outpatient care: 
physician visits, urgent 
care visits, 
emergency room visits  
Prescriptions: total 
number of prescription 
claims, 
total number of unique 
claims 
USD  Pre-infection annual per-patient 
medical expenditures were 
$33,305. 
 After infection, annual per-
patient expenditures increased to 
$51,821, a jump of more than 
$18,500 relative to baseline 
value. 
 Inpatient care was the single 
largest contributing factor, with 













To compare costs and 
discharge rates among 
adult CF patient 
hospitalizations in terms 
of location of 
hospitalization. 
National Inpatient 
Sample from HCUP  
Hospital Charges 2007, USD  Adjusted mean hospital charges 
had no difference for patients in 
pediatric ($53,095) and adult 
($59,627) hospitals 
Briesacher 





To provide the first 
comprehensive 
evaluation of changes in 
CF healthcare costs over 
time and report overall 
annual trends in out- 
patient visits, inpatient 
admissions, and 
prescription drug use 
between 2001 and 2007 
for a national sample of 










Total costs, included 
inpatient costs, 
outpatient costs, and 
prescription drug use. 
2007, USD  Overall, the yearly costs per 
person of prescription drugs, 
outpatient visits, and durable 
medical equipment increased by 
61% during the 7-year period 
($18,715 in 2001 vs. $29,718 in 
2007). 
 Outpatient medical care costs 
increased, on average, 57% from 
$7,648 in 2001 to $12,040 in 
2007 
 Prescription drugs increased 
66% ($10,121 in 2001 to 
$16,804 in 2007).  
 Largest increases in total 
medical care costs occurred for 
the oldest CF patients  
O’Sullivan 





To examine health care 
utilization and costs over 
one year among CF 
patients with pulmonary 
infections. 
Medical and 
pharmacy claims data 
for commercial and 
Medicaid enrollees 
from a large US 
health plan 
Physician office visits, 
out- patient hospital 
visits, ER visits, in- 
patient stays, and 
prescription drugs. 
2006, USD  Mean annual costs for CF 
totaling about $29,000 per 
patient plus another $20,000 for 
prescription drugs. 
 Inpatient hospital costs were 
$22,102 for CF-related stays and 













To characterize annual 
medical expenditures 
incurred by people with a 
medical diagnosis of CF 
among a privately 







and enrollment across 
inpatient, outpatient, and 
prescription drug 
services. 
2006, USD  Total medical care expenditures 
averaged $48,098 for people 
with CF, more than 22 times the 
average of $2,172 for people 
without CF.  
 People with CF had mean annual 
expenditures for inpatient care 
that were 35 times higher 
($16,545 vs. $467) than those for 
people without CF.  
 Expenditures for prescribed 
medications were 42 times 
higher ($18,461 vs. $437) among 
those in the CF group.  
 Average expenditures for 
outpatient visits were 10 times 
higher ($13,092 vs. $1,267) for 
those with CF than for those 
without CF. 







This study has a few limitations that should be considered. The heterogeneity of 
the literature (among populations, treatments, measurements, and outcomes) identified in 
this review made individualized quality assessments of the studies using a particular 
method extremely difficult. Though we tried to incorporate both international and US 
studies in our review, international non-English studies containing relevant information 
might have been excluded. Also, readers need to account for any differences in the 
healthcare systems before interpreting the results of US and international studies.    
 
CONCLUSIONS 
 This systematic review provides a comprehensive summary of the studies that 
have estimated the burden of CF over the last decade. Among these, very few studies 
have included the cost of CFTR modulator therapies and even the few that have, only 
focused on one CFTR modulator therapy (ivacaftor). With three high acquisition cost 
CFTR modulator therapies currently in the market, there is a need to provide a more 
current estimate of the economic burden associated with CF, especially focusing on 





CHAPTER 3: METHODS 
 
The overall goal of the study was to assess the utilization of CFTR modulator 
therapies in patients with CF. Utilization data on CFTR modulator therapies was sourced 
from AllianceRx Walgreens Prime specialty pharmacy, one of the nation’s largest 
specialty pharmacy providers. The study was approved by the Institutional Review Board 
(IRB) of Duquesne University and the legal team of AllianceRx Walgreens Prime 
specialty pharmacy.  
This chapter includes a detailed description of the specialty pharmacy database, 
study variables and the analytical techniques employed in the study. 
 
ALLIANCERX WALGREENS PRIME SPECIALTY PHARMACY 
DATABASE 
 AllianceRx Walgreens Prime specialty pharmacy offers various services from 
refilling and shipping of specialty medications to counseling patients regarding 
medication adherence and adverse events associated with medications. As per their 
protocol, data is captured in an electronic format using pre-defined variables at each step 
of the process. For this study, de-identified data from patients with CF using CFTR 
modulator therapies (Kalydeco, Orkambi and Symdeko) was provided by AllianceRx 
Walgreens Prime specialty pharmacy to the researchers.   
Depending on the point of data collection, the data can be broadly categorized 
into two parts: refill data of CFTR modulator therapy and routine patient assessment data. 
During the collection of the refill data, patient’s demographics, medication information 
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and insurance details are collected. For this study, refill data from 1st January 2015 to 31st 
August 2018 was provided by the AllianceRx Walgreens Prime specialty pharmacy. For 
the specific study variables included in the refill data refer Table 5. 
The second data included in the study was the routine patient assessment data, 
which is collected during the induction of the patient in the pharmacy, generally when 
filling the first prescription. A patient care coordinator (PCC) and a pharmacist complete 
the initial patient assessment. Additionally, before each refill, a PCC administers a refill 
assessment survey that provides information on medication switching, discontinuation, 
missed doses and any side-effects that the patient may be experiencing. If the patient has 
specific concerns, the case gets escalated to a pharmacist who then completes the 
assessment and counsels the patient on the specific problem. At each stage of the process, 
the patient responses are documented in the electronic dataset. For this study, patient 
assessment data from 30th April 2014 to 30th August 2018 was provided by AllianceRx 
Walgreens Prime specialty pharmacy. Table 6 lists the study variables from the patient 
assessment dataset were utilized in the analyses. 
 
DATA EXTRACTION 
 The researchers worked alongside a team of AllianceRx Walgreens specialty 
pharmacy employees to identify variables needed for these analyses. The data extraction 
for these variables was then conducted by AllianceRx Walgreens specialty pharmacy and 
de-identified files were provided to researchers at Duquesne University. These de-
identified datasets consisted of the exact constraints needed for the study hence no further 
cleaning of the data was necessary. In the refill data file extracted from the specialty  
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Table 5: Variables included in the refill data  
 
Variables included in the refill data 
Patient ID Drug Name Secondary Payer Name  
Patient Age Quantity Secondary Payer Type 
Patient Sex Day Supply Secondary Copay 
Patient State WAC ICD Codes 
Refill Number Price Allergy 
Fill Date Primary Payer Name Other Medications 
Ship Date  Primary Copay  
 
Table 6: Variables present in the patient assessment dataset 
Variables present in the patient assessment dataset 
Patient ID Side Effects Reason Question ID 
Assessment Date Side Effects Reason Question  
Drug Name Side Effects Reason Response 
Discontinued Medication Question ID Missed Doses Reason Question ID 
Discontinued Medication Question Missed Doses Reason Question 
Discontinued Medication Response Missed Doses Reason Response 




pharmacy dispensing system, each row represented a new fill or a refill for a patient. 
Similarly, in the patient assessment data extracted from the specialty pharmacy clinical 
system, each row represented a response of the patient to a particular question asked by a 
PCC or a pharmacist during each patient encounter. Thus, in both files, a single patient 
can have multiple rows of data. After the Excel files were received by researchers at 
Duquesne University, they were converted into Statistical Analysis System (SAS) files 
(SAS Institute University Edition; Cary, NC) dataset. Further analyses were performed 
using both excel and SAS files. All the SAS codes used for data extraction and analyses 
are attached in Appendix II. 
STUDY VARIABLES 
The variables from refill and patient assessment data used in this study are described in 
Table 7. 
DATA ANALYSIS 
In this section, the analytical techniques for each study objective are described. 
Objective 1 
To describe the demographics, medication utilization, and insurance characteristics for 
patients on CFTR modulator therapies. 
Descriptive analyses (mean, standard deviation, median, and frequency 
distribution) were conducted to provide a distribution of patient (age, sex, and residence) 
and clinical factors (co-morbidities and allergies). Further, all medication utilization and 
insurance characteristics were described using the data collected on the last refill (most 




Table 7: Variable Descriptions 
Variable Name Description 
Patient ID A unique identifier was assigned to each patient in the 
AllianceRx Walgreens Prime specialty pharmacy database. 
Age The patient’s date of birth was utilized to calculate the age as on 
30th January 2019. For further analyses, two age categories were 
created: ‘below 18 years’ and ‘equal to or greater than 18 years.’  
Sex Sex was categorized as male or female. 
Area of Residence 
 
The state in which the patient resides was used to create four 
regions of the US: Northeast, Midwest, South and West. 
Allergy 
 
Patient’s self-reported allergies were captured in the refill data 
set and were presented as none, one or more than one allergy. 
Co-morbidity Patient reported all the medical conditions they suffered from 
including CF. These were reported in the database in the form of 
ICD-9 and ICD-10 codes. Patients could have none, one, or 
more than one co-morbidity. The co-morbidities are categorized 




The insurance details for each refill filled by the patient included 
the name and type of primary insurance plan. The name and type 
of secondary insurance plan was also included if the patient had 
enrolled into one. Both primary and secondary insurance plans 
were further categorized into government, commercial, and 
charitable organizations.   
Co-pay The copay for primary and secondary insurance for each fill and 
refill was recorded in the datasets. 
Drug Name 
 
The drug name was recorded during each fill and refill. Given 
the focus of the study on CFTR modulator therapies, Orkambi, 
Kalydeco and Symdeko records were identified in the datasets. 
Fill Date 
 
The date at which the prescription was filled or refilled for any 




Medication adherence to CFTR modulator therapies was 
calculated using PDC as a measurement. The formula utilized 
for calculating PDC is as follows: 
 PDC= (Number of days in period “covered”/Number of 
days in period) 
The value of PDC ranged from 0 to 1, where 0 indicated an 
adherence of 0% whereas 1 indicated 100% adherence. Given 
the possibility of patients switching from one CFTR modulator 
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therapy to another during the study period, a patient can have 
two different PDC values for different medications. 
Other Medications The medications (other than CFTR modulator therapies) that the 
patients take are self-reported in the database. The variable 
includes the names of the medications which were further 
utilized to estimate the burden of the disease. 
 
Table 8: Categories of co-morbidities 
 
Diseases ICD-9 codes ICD-10 codes 
Infectious and parasitic diseases  001-139 A00-B99 
Neoplasms  140-239 C00-D009 
Endocrine, nutritional and metabolic diseases, and 
immunity disorders, diseases of the blood and blood-
forming organs   
240-289 D50-D89, 
E00-E89 
Mental disorders  290-319 F01-F99 
Diseases of the nervous system and sense organs  320-389 G00-H95 
Diseases of the circulatory system  390-459 I00-I99 
Diseases of the respiratory system  460-519 J00-J99 
Diseases of the digestive system  520-579 K00-K95 
Diseases of the genitourinary system  580-629 N00-N99 
Complications of pregnancy, childbirth, and the 
puerperium  
630-677 O00-O9A 
Diseases of the skin and subcutaneous tissue  680-709 L00-L99 
Diseases of the musculoskeletal system and 
connective tissue  
710-739 M00-M99 
Congenital anomalies  740-759 Q00-Q99 
Certain conditions originating in the perinatal period  760-779 P00-P96 
Symptoms, signs, and ill-defined conditions  780-799 R00-R99 






To identify reasons for missed doses, medication discontinuation, and CFTR modulator 
therapy-related adverse events  
Responses regarding discontinuation, missing doses and adverse events associated 
with the use CFTR modulator therapies extracted from patient assessments were 
analyzed. Because the responses were collected over a span of over five years, there is a 
probability that the same question could have been asked to the same patient at multiple 
time points. Hence, the frequency was calculated using the number of responses as a unit 
of measurement. The most frequent responses provided by the patients was identified for 
each question.  
 
Objective 3 
To calculate medication adherence rate using PDC as a measure for patients with more 
than one refill for CFTR modulator therapies and explore the association between 
medication adherence rate and payer characteristics (those with and without secondary 
insurance). 
Fill dates for CFTR modulator therapies were utilized to calculate PDC for each 
CFTR modulator therapy that a patient was on. Further, the overall PDC values for each 
CFTR modulator therapy were categorized using age and insurance characteristics. Since 
there is a possibility that during the entire study period (2015-2018) the patients may 
enter, leave and then re-enter the system at different time points due to various reasons, 
the calculated PDC may have some limitations. To overcome these limitations PDC was 
also calculated for only one year (September 2017- August 2018) of the study period. 
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Further, since there is a possibility of patients switching CFTR modulator therapies 
during a year, PDC values were also calculated only for patients who haven’t switched 
from one CFTR modulator therapy to the other in a year. These PDC values aided in 
comparing the adherence of patients on different CFTR modulator therapies.  
 
Objective 4 
To analyze the spending pattern of the specialty pharmacy on CFTR modulator therapies 
from 2015-2018. 
Number of prescriptions dispensed every year for each CFTR modulator therapy 
identified from the refill database were multiplied with the WAC (price obtained from the 




To identify the average co-pay of patients for CFTR modulator therapies based on payer 
type. 
Mean co-pay for each CFTR modulator therapy was calculated using co-pay 
amount collected during the refill of medications. This was further categorized based on 
patient’s insurance data (e.g., with or without secondary insurance). Further, mean values 
of co-pay were also categorized using the type of insurance i.e. government, commercial 
or charitable organizations for either primary or both primary and secondary insurances. 





To estimate the burden of medications (Other CF & non-CF medications) in the CF 
population 
Unique medications (except CFTR modulator therapies) reported by the patients 
were identified from the databases. To estimate the burden of these medications, their 
WAC values (lowest and highest) was obtained from the Red Book. The medications 
were then grouped according to their therapeutic class and overall WAC values (lowest 
and highest values) were estimated which provided the burden of these medications on 





CHAPTER 4: RESULTS 
OBJECTIVE 1 
To describe the demographics, medication utilization, and insurance characteristics for 
patients on CFTR modulator therapies. 
Descriptive analyses were conducted using the last refill data of patients on CFTR 
modulator therapies. A total of 4,444 unique patients were identified in the database from 
2015-2018. This included 2,857 (64.29%) adults (age equal to or above 18 years) and 
1,587 (35.71%) children/ adolescents (age less than 18 years).  
Table 9 describes the demographic and medication utilization characteristics such 
as age, sex, patient residence and CFTR modulator therapies for this population. The age 
of the patients ranged from 1 to 88 years with a mean of 24.41±13.33 years. The sex 
distribution of males and females was fairly even (p-value >0.05) across both age groups 
(children/adolescents and adults) and in the overall sample. Conversely, a significant 
difference was observed in the patient residence characteristics amongst 
children/adolescents and adults (p=0.0007). 
Based on the medication utilization characteristics, most patients were on 
Orkambi (48.80%) followed by Kalydeco (28.00%) and Symdeko (23.20%). Also, a 
statistical significance was also found in the difference in medication utilization 
characteristics among children/adolescents and adults (p<0.00001).  
Table 10 describes the insurance characteristics for the patients on CFTR 
modulator therapies based on their last refill data. A majority of patients (62.85%) only 
had primary insurance. Commercial insurance (52.88%) was the main type of primary 
insurance with the rest having some form of government insurance (47.18%). 
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Table 9:Demographics and medical utilization characteristics of the patients (Based 
on last refill data) 
 









Age in years 




24.41 ± 13.33 
22 
 
11.80 ± 3.82 
12 
 
31.42 ± 11.43 
29 
<0.0001 
Sex (n, %) 
 
   
Female 2101, 47.28% 761, 47.95% 1340, 46.90% 0.57 
Male 2343, 52.72% 826, 52.05% 1517, 53.10% 
Patient Residence (n, %) 
 
   
Northeast 839, 18.88% 263, 16.57% 576, 20.16% 0.0007 
Midwest 1199, 26.98% 452, 28.48% 747, 26.15% 
South  1664, 37.44% 633, 39.89% 1031, 36.09% 
West 742, 16.70% 239, 15.06% 503, 17.61% 
CFTR Modulator Therapies 
(n, %) 
    
Kalydeco 1247, 28% 468, 39.49% 779, 27.27% <0.00001 
Orkambi 2167, 48.8% 904, 56.96% 1263, 44.21% 
Symdeko 1030, 23.2% 215, 13.55% 815, 28.53% 
Comparing children/adolescents versus adults using chi-square test 
Significance p  0.05 
 












Only Primary Insurance  2793, 62.85% 1058, 66.67% 1735, 60.73% 
Government 1316, 47.12% 578, 54.63% 738, 42.54% 
Commercial 1477, 52.88% 480, 45.37% 997, 57.46% 
Primary and Secondary Insurance 1651, 37.15% 529, 33.33% 1122, 39.27% 
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Children/adolescents were mostly on government insurance (54.63%) while the adults 
were on commercial insurance (57.46%). For patients with both primary and secondary 
insurances, commercial (primary) and commercial (secondary) (80.57%) were the most 
observed set of insurances (Refer Table 11). 
Finally, the leading co-morbid condition in these patients was endocrine, 
nutritional, metabolic and immunity disorders, diseases of the blood and blood-forming 
organs (56.83%) (Refer Table 12). Most patients reported that they do not have any 
known drug allergy (69.07%). All the co-morbidities and allergies are listed in the 
Appendices III and IV, respectively.  
 
OBJECTIVE 2 
To identify reasons for missed doses, medication discontinuation, and CFTR modulator 
therapy-related adverse events  
The routine patient assessments collected by PCC were analyzed to explore the 
reasons for missing doses and discontinuation of CFTR modulator therapies, and identify 
adverse events related to these therapies. Patients reported switching of medications 
(n=185, 74.90%) as the most frequent reason for discontinuing medications. Orkambi 
(n=205, 62.69%) was reported to be discontinued the most. (Refer Tables 13 and 14).  
Regarding patient responses to the question on missed doses in the past 28 days, a 
majority of them taking Orkambi (n=24443, 92.23%) or Kalydeco (n=13985, 93.83%) 
reported not missing any doses (Refer Table 15). Close to five percent of patients did 
report missing one to five doses of both Orkambi and Kalydeco.  The most frequent 
reason for missing doses was forgetfulness for Kalydeco (n=366, 45.64%),  
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Table 11:Insurance characteristics of patients on primary and secondary insurance (Based on last refill data)  
 








Commercial  Government  Commercial  Government  Commercial  Government 
Commercial 1329, 80.57% 191, 11.57% 420, 79.40% 99, 18.71% 909, 81.02% 92, 8.20% 
Government 110, 6.66% 21, 1.27% 8, 1.51% 2, 0.38% 102, 9.09% 19, 1.69% 
 
Table 12: Top patient reported co-morbidities 




Endocrine, nutritional and metabolic diseases, and immunity disorders, diseases of the blood 
and blood-forming organs   
4770 56.83 
Diseases of the respiratory system  1143 13.62 
Infectious and parasitic diseases  563 6.71 
Diseases of the digestive system  496 5.91 
Symptoms, signs, and ill-defined conditions  375 4.47 
 
 56 
Table 13: Reasons for discontinuing medications 
Question Why was the medication discontinued? 
 
Response Frequency  
n=247 
Percent (%) 
Switched medication  185 74.90 
Other (document in comments section below)  23 9.31 
Uncertain  22 8.91 
Side effects  12 4.86 
Lab abnormalities  2 0.81 
Administration difficulties  1 0.40 
Allergic reaction  1 0.40 
Financial issues  1 0.40 
Sample size only included responses to this specific question  
Table 14: Discontinued medications 
Question Patient's medication(s) that is/are being discontinued 
Response Frequency  
n=327 
Percent (%) 
Kalydeco  62 18.96 
Orkambi  205 62.69 
Symdeko  10 3.06 
Non-CFTR modulator therapies 50 15.29 
Sample size only included responses to this specific question 
Table 15: Frequency of missing doses 
Question In the past 28 days, how many 
doses of your Orkambi would you 
say you missed or skipped? 
In the past 28 days, how many 
doses of your Kalydeco would 
you say you missed or 
skipped? 
Response Frequency  
n=25840 
Percent (%) Frequency  
n=14905 
Percent (%) 
0 24443 92.23 13985 93.83 
1 to 5  1273 4.80 686 4.60 
6 to 11  55 0.21 47 0.32 
12 or more 69 0.26 33 0.22 
Not filling drug today  509 1.92 150 1.01 
Unsure  153 0.58 4 0.03 
Sample size only included responses to these specific question  
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Orkambi (n=688, 59.98%) and Symdeko (n=29, 53.70%). Some patients on Kalydeco (n=157, 
19.58 %), Orkambi (n=222, 19.35%) and Symdeko (n=6, 11.11%) even responded that “they 
were too busy” or “were unable to fit it into their daily routine” as a reason for missing doses 
(Refer Table 16). Majority of patients on Kalydeco (n= 8947, 96.36%), Orkambi (n=13531, 
93.48%) or Symdeko (n=1412, 82.96%) did not report any adverse events associated with the 
three therapies (Refer Table 17). 
 
OBJECTIVE 3 
To calculate medication adherence rate using PDC as a measure for patients with more than one 
refill for CFTR modulator therapies and explore the association between medication adherence 
rate and payer characteristics (those with and without secondary insurance). 
PDC was calculated for the following time periods—entire study period (January 2015- 
August 2018), one year (September 2017- August 2018) and for patients who did not switched 
from one CFTR modulator therapy to another in one year (September 2017- August 2018). PDC 
was calculated for both the age groups (children/adolescents and adults) and insurance 
characteristics (those with only primary insurance and those with both primary and secondary 
insurances). Overall, the average PDC values exceeded the threshold of 0.8 except for adults on 
Orkambi over the entire study period (0.79). Also, it was seen that overall and across all 
categories (age and insurance characteristics), Symdeko had the highest PDC (>0.91) when 







Table 16: Reasons for missing doses 
Question What causes you to 
miss your Kalydeco? 
What causes you to miss 
your Orkambi? 












Forgetfulness  366 45.64 688 59.98 29 53.70 
Too busy/Unable to fit into daily 
routine  
157 19.58 222 19.35 6 11.11 
Vacation/Away from home  34 4.24 81 7.06 1 1.85 
Insurance issues (Prior Auth)  36 4.49 76 6.63 1 1.85 
Infection/Illness  32 3.99 38 3.31   
Surgery  11 1.37 12 1.05   
Financial issues  4 0.50 11 0.96   
Administration difficulties  2 0.25 7 0.61 2 3.70 
Side effects  2 0.25 7 0.61 1 1.85 
Dose or frequency changed  3 0.37 5 0.44   
Other (document in comments 
section below)  
117 14.59   13 24.07 
Lapse in access or waiting for 
delivery 
38 4.74   1 1.85 











Table 17: Adverse events reported for CFTR modulator therapies 
Question What side effects, if any, 
are you experiencing with 
your Kalydeco? 
What side effects, if 
any, are you 
experiencing with 
your Orkambi? 
What side effects, if any, 
are you experiencing 













None  8947 96.36 13531 93.48 1412 82.96 
Not filling drug today* 156 1.68 537 3.71 197 11.57 
Other (document in comments section 
below)  
97 1.04 152 1.05 57 3.35 
Headache  27 0.29   16 0.94 
Rash  12 0.13     
Upper respiratory tract infection  10 0.11 7 0.05   
Oropharyngeal pain (mouth or throat 
discomfort) 
6 0.06     
Symptoms of liver problems (dark urine, 
loss of appetite, stomach pain or 
discomfort, unusual nausea or vomiting, 
yellowing of the skin or eyes)  
6 0.06 9 0.06   
Nasopharyngitis (cold symptoms, runny 
nose, sneezing)  
5 0.05 13 0.09   
Nasal congestion  3 0.03   1 0.06 
Chest tightness 
  
75 0.52   
GI symptoms (nausea, diarrhea, gas) 13 0.14 54 0.37 10 0.59 
Dyspnea (shortness of breath)   52 0.36   
Fatigue   24 0.17   
Menstrual problems (irregular, missed or 
abnormal periods or increase in the 
amount of bleeding) 






Muscle Pain   4 0.03   
Vision changes 1 0.01   2 0.12 
Dizziness     4 0.24 
*During regular follow ups, the system provides the PCC the option to enter this response if the patient is not filling any 
particular medication while the assessment 
Sample size only included responses to these specific question  
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For the entire study period, a total of 4569 PDC values were calculated. This number is 
higher than the number of unique patients (4444) as some patients had switched from one CFTR 
modulator therapy to another resulting in more PDC values than the study sample. The overall 
PDC for the entire study period for all CFTR modulator therapies was 0.83. The average PDC 
over the one-year period (n=3482) was 0.87 and among patients who did not switch from one 
CFTR modulator therapy to another in this one-year period was 0.86 (Refer Tables 18, 19 and 
20). 
Among patients who did not switch medications over a one-year period (September 
2017- August 2018), it was observed that children/ adolescents on Orkambi (p-value=0.0001) 
and Symdeko (p-value=0.001) had significantly higher PDC values when compared to adults. 
Across both the insurance characteristics of patients who did not switch medications in a year 
(September 2017- August 2018), no particular pattern emerged, and it was seen that the PDC 
was majorly similar with some marginal differences.  
 
OBJECTIVE 4 
To analyze the spending pattern of the specialty pharmacy on CFTR modulator therapies from 
2015-2018. 
The spending patterns of the specialty pharmacy was estimated based on the number of 
prescriptions dispensed each year for each CFTR modulator therapy and WAC pricing adjusted 
to 2018-dollar values using the Bureau of Labor Statistics data. Amongst the CFTR modulator 






Table 18: PDC calculated using fill dates from the entire study period (2015- August 2018) 
(A) Overall PDC  
Overall 
 
n Mean ± SD 
Total 4569 0.83 ± 0.18 
Kalydeco 1225 0.81 ± 0.18 
Orkambi 2479 0.81 ± 0.18 
Symdeko 865 0.92 ± 0.11 
 
(B) PDC categorized according to age 
 Children/ Adolescents Adults 
 n Mean ± SD n Mean ± SD 
Total 1596 0.85 ± 0.16 2973 0.82 ± 0.18 
Kalydeco 450 0.83 ± 0.16 775 0.80 ± 0.19 
Orkambi 968 0.84 ± 0.16 1511 0.79 ± 0.19 
Symdeko 178 0.94 ± 0.11 687 0.92 ± 0.11 
 
(C) PDC categorized according to insurance characteristics  
Individuals with only Primary Insurance Individuals with Primary and Secondary Insurance 
 
n Mean ± SD n Mean ± SD 
Total 2838 0.83 ± 0.17 1731 0.83 ± 0.18  
Kalydeco 727 0.81 ± 0.18 498 0.82 ± 0.19 
Orkambi 1598 0.81 ± 0.18 881 0.80 ± 0.19 








Table 19: PDC calculated using fill dates for one year (September 2017- August 2018) 
(A) Overall PDC  
Overall  
n Mean ± SD 
Total 3482 0.87 ± 0.14 
Kalydeco 850 0.85 ± 0.15 
Orkambi 1767 0.85 ± 0.14 
Symdeko 865 0.92 ± 0.11 
 
(B) PDC categorized according to age 
 Children/ Adolescents Adults 
 n Mean ± SD n Mean ± SD 
Total 1309 0.87 ± 0.14 2173 0.86 ± 0.14 
Kalydeco 338 0.85 ± 0.15 512 0.84 ± 0.16 
Orkambi 793 0.86 ± 0.13 974 0.83 ± 0.15 
Symdeko 178 0.94 ± 0.11 687 0.92 ± 0.11 
 
(C) PDC categorized according to insurance characteristics  
Individuals with only Primary 
Insurance 
Individuals with Primary and 
Secondary Insurance 
 
n Mean ± SD n Mean ± SD 
Total 2110 0.87 ± 0.14 1372 0.87 ± 0.14  
Kalydeco 482 0.84 ± 0.16 368 0.85 ±0.15 
Orkambi 1115 0.85 ± 0.14 652 0.84 ± 0.14 








Table 20: PDC calculated for all patients who did not switched medications in one year (September 2017- August 2018) 
(A) Overall PDC  
Overall  
n Mean ± SD 
Total 2548 0.86 ± 0.15 
Kalydeco 789 0.84 ± 0.16 
Orkambi 1361 0.84 ± 0.15 
Symdeko 398 0.92 ± 0.11 
 
(B) PDC categorized according to age 
 Children/ Adolescents Adults p-value 
 n Mean ± SD n Mean ± SD  
Total 1075 0.86 ± 0.14 1473 0.85 ± 0.15 0.0876 
Kalydeco 330 0.85 ± 0.15 459 0.84 ± 0.16 0.3744 
Orkambi 684 0.86 ± 0.14 677 0.83 ± 0.15 0.0001 
Symdeko 61 0.96 ± 0.10 337 0.91 ± 0.11 0.001 
Comparing children/adolescents versus adults using t-test 
Significance p  0.05 
 
(C) PDC categorized according to insurance characteristics  
Individuals with only Primary 
Insurance 




n Mean ± SD n Mean ± SD  
Total 1564 0.86 ± 0.15 984 0.86 ± 0.15 1.00 
Kalydeco 455 0.84 ± 0.16 334 0.84 ± 0.16 1.00 
Orkambi 869 0.85 ± 0.15 492 0.84 ± 0.15 0.24 
Symdeko 240 0.92 ± 0.12 158 0.92 ± 0.11 1.00 
Comparing individuals with only primary insurance versus individuals with primary and secondary insurance using t-test 
Significance p  0.05 
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million in 2015 to $281 million in 2017. However, the spending on Kalydeco remained 
fairly constant over the years with $103 million spent in 2015 to $119 million in $2017. 
Additionally, the introduction of Symdeko did not offset the specialty pharmacy’s 
spending on Orkambi ($183 million) and Kalydeco ($114 million) till August 2018 
(Refer Table 21 and Figure 7). 
 
OBJECTIVE 5 
To identify the average co-pay of patients for CFTR modulator therapies based on payer 
type. 
Average co-pay was calculated for all CFTR modulator therapies from January 
2015- August 2018 across all insurance characteristics. A non-linear trend was observed 
for the average co-pay of all CFTR modulator therapies over this time period (Refer 
Figure 8). While the co-pay for Kalydeco increased from $247.14 in 2015 to $292.36 in 
2017, there was a drop in co-pay for Orkambi in 2016 followed by an increase to $173.35 
in 2017. It was also observed that the average co-pay for 2018 was the highest among all 
the years across all CFTR modulator therapies.  
A huge range was observed in the co-pay values were observed for all CFTR 
modulator therapies across all years (Refer Table 22). The highest range was observed in 
2015 for Orkambi where the minimum co-pay value was $0 while the maximum was 
$33309.57. For patients with only primary government insurance, the average co-pay 
ranged from $0-$40 and for those on commercial insurance, it ranged from $20-$310 










2015 2016 2017 2018* 
Kalydeco 4347 4899 4999 4794 
Orkambi 3223 9642 13449 8763 
Symdeko - - - 3842 
*Number of prescriptions calculated only till August 2018 
Symdeko launched in 2018  
 
Table 22: Range of co-pay 
 
Range of Co-pay  
  All drugs Kalydeco  Orkambi Symdeko 
  Min Max Min Max Min Max Min Max 
2015 $0 $33309.57 $0 $27754.95 $0 $33309.57 
  
2016 $0 $25517.72 $0 $25517.72 $0 $21049.72 
  
2017 $0 $23825.14 $0 $23825.14 $0 $22745.96 
  
2018 $0 $24494.49 $0 $24494.49 $0 $22339.76 $0 $22822.37 
 
 
Table 23: Co-pay for people on only primary insurance 
  
Kalydeco Orkambi Symdeko 
  Government  Commercial Overall Government  Commercial Overall Government  Commercial Overall 
2015 $3.82 $309.42 $184.68 $10.88 $25.63 $20.20       
2016 $2.31 $297.13 $156.05 $0.80 $19.98 $10.63       
2017 $16.82 $197.58 $109.20 $1.76 $124.16 $60.30       
2018 $12.21 $160.75 $87.31 $0.55 $146.06 $66.41 $38.14 $203.84 $135.18 
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Figure 7: Spending pattern of the specialty pharmacy 
 
2015 2016 2017
Orkambi $67,422,678 $201,703,216 $281,342,724




























Figure 8: Trends in average co-pay 
2015 2016 2017 2018
Kalydeco $247.14 $271.65 $292.36 $396.00



























*Calculated using data till August 2018
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co-pay of $12.21 in 2018 compared to those on commercial insurance whose copay was 
$160.75 in 2018. Similarly, for patients on government insurance, the average co-pay for 
Orkambi was $0.55 in 2018 while for those on commercial insurance, it was $146.06 in 
2018. With the introduction of Symdeko in 2018, the average co-pay for patients on 
government insurance was $38.14 and for those on commercial insurance, it was 
$203.84. (Refer Table 23). 
For patients who had both primary and secondary insurances, the secondary co-
pay over all the years (January 2015-August 2018) ranged from $0-$35. Patients whose 
primary and secondary insurances were commercial in nature had a similar co-pay for all 
three CFTR modulator therapies and it ranged from $12-$22. The average co-pay in 2018 
for all CFTR modulator therapies for patients enrolled in government primary and 
secondary insurances was observed to be $0 (Refer Table 24). 
 
OBJECTIVE 6 
To estimate the burden of medications (CF related & non-CF related medications) in the 
CF population 
 To estimate the overall burden of medications on patients with CF, all the 
medications (other than CFTR modulator therapies) listed under the patients’ names were 
categorized into therapeutic areas and a total value was calculated based on the WAC 
costs from the 2018 Red Book. The therapeutic categories were created by combining 
medications in similar therapeutic class. For example, antidepressants, antiepileptics and, 
anxiolytics were categorized under the therapeutic category of CNS and mental health. A 
total of 10,838 medications were recorded in the database and these were combined into 






Table 24: Co-pay for people on primary and secondary insurance 
 
(A) Primary Insurance - Commercial & Secondary Insurance – Commercial  
  




























$12.9  $5.49 $747.41  
$2105 
$21.95   
$226.45 












$603.05   
$1929 
$15.17   
$135.91 
Symdeko 
      
$372.78   
$1910 
$13.41   
$34.82 
 
(B) Primary Insurance - Commercial & Secondary Insurance – Government 
  































































(C) Primary Insurance - Government & Secondary Insurance - Government 
  





































$0  $0 $218.65  
$1020 
$0  $0 $238.5  
$523.35 
$0.25  $0.83 $610.29  
$1050 
$0  $0 
Symdeko 
      
$266.6  
$486.59 
$0  $0 
 
(D) Primary Insurance - Government & Secondary Insurance – Charitable Organizations  
  
















































0.8  3.37 
Symdeko 









14 therapeutic categories. The most widely reported therapeutic class included anti-infectives 
(22.81%), respiratory (20.23%), and electrolytes and dietary supplements (15.69%) (Refer Table 
25). The most frequently listed medications were antibiotics (20.95%), anti-inflammatory 
(12.70%) and bronchodilators (11.47%) (Refer Table 26). 
 The economic burden of these medications was calculated using the lowest and highest 
WAC value obtained from the Red Book. Across all the medications the lowest WAC was 
observed for an iron supplement ($0.2) while the highest was for an ovulation stimulant 
($98,175) (Refer Table 26). Similarly, the categories created had a wide range due to a variation 
in costs, which was based on different strength and package sizes. Though anti-infectives had the 
highest utilization as reported by their frequency of use, their cost ranged from $0.58 to 
$8,009.77. Respiratory medications had a similar range from $0.64 to $8,127.50. The broadest 
range was observed for medications categorized in endocrine and sexual health, with a low of 






Table 25: Overall economic burden of different therapeutic categories in patients with CF 








Anti-infectives 2472 22.81 0.58 8009.77 
Respiratory  2192 20.23 0.64 8127.50 
Electrolytes and dietary supplements 1701 15.69 0.20 63592.75 
Analgesics  1454 13.42 0.71 15522.32 
Enzyme replacement 894 8.25 74.30 2339.79 
Gastrointestinal agents 834 7.70 0.49 33955.80 
CNS and mental health 444 4.10 1.35 32336.16 
Endocrine and sexual health 368 3.40 1.12 98175.00 
Cardiovascular  161 1.49 0.40 59433.91 
Miscellaneous  132 1.22 3.52 8210.64 
Medical device 118 1.09 3.23 140.23 
Blood 41 0.38 0.38 9297.70 
Dermatological 22 0.20 0.27 22004.61 
Ophthalmic 5 0.05 1.39 451.19 
*2018 WAC obtained from Red book 




Table 26: Burden of medications under each therapeutic class in patients with CF 









Anti-inflammatory 1376 12.70 0.79 15522.32 
Analgesic 64 0.59 0.71 8080.91 
Antipyretic 14 0.13 3 319.66 
Anti-infectives  
Antibiotic 2271 20.95 1.43 8009.77 
Antifungal 75 0.69 0.58 6166.39 
Antiviral 66 0.61 11.31 2889.36 
Viral Vaccine 44 0.41 168.2   
Antimalarial 7 0.06 16.25 1553.25 
Antitubercular 5 0.05 37.99 130 
Antimicrobial 4 0.04 3.73 60.5 
Anti-Hepatitis C 1 0.01 695.6   
Blood 
Anticoagulant 32 0.30 0.38 14932.9 
Antifibrinolytic 6 0.06 9 2794.98 
Antianemia 2 0.02 165.8 9297.7 
Antiplatelet agent 1 0.01 580.09   
Cardiovascular  
Antihypertensive 107 0.99 0.4 11181.24 
Antihyperlipidemic 48 0.44 0.86 59433.91 
Diuretic 3 0.03 1.65 584 
Antihypertriglyceridemic 2 0.02 299.35   
CNS and mental health 
Antidepressant 167 1.54 1.35 1985 
Antiepileptic 54 0.50 1.7 28235.53 
Anxiolytic 58 0.55 1.99 32336.16 
CNS stimulant 42 0.39 18 1811.25 
Anti-ADHD 38 0.35 85 1012.8 
Antipsychotic 25 0.23 10 9522.8 
Skeletal muscle relaxant 18 0.17 7.75 5083.37 
Hypnotic 13 0.12 4.61 4023.44 
ADHD agent 10 0.09 63.27 1459.5 
Antimigraine 8 0.07 14.75 952.2 
Mood stabilizers 5 0.05 6.48 788 
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Antiparkinson 4 0.04 99.29 744.83 
Antimuscarinic 2 0.02 72.13 484.77 
Dermatological 
Antiacne 15 0.14 5.85 3104.51 
Keratolytic 3 0.03 5.74 3540 
Antiseptic 2 0.02 0.53 15300 
Antipruritic 1 0.01 0.27   
Antipsoriatic 1 0.01 1600 22004.61 
Electrolytes and dietary supplements 
Multivitamin 597 5.51 1.18 63592.75 
Calcium supplement 376 3.47 0.97 1486.82 
Sodium supplement  367 3.39 1.62 250 
Nutritive agent 197 1.82 1.18 5876.01 
Probiotic 66 0.61 2.59 85 
Iron supplement 42 0.39 0.2 53.16 
Electrolyte supplement 38 0.35 0.94 2.1 
Fluoride supplement 7 0.06 3.78 796.47 
Potassium supplement  5 0.05 0.5 2258.5 
Calcium regulator 3 0.03 340.98 2437.85 
Folic acid supplement 3 0.03 503.07   
Enzyme replacement 
Enzyme replacement 894 8.25 74.3 2339.79 
Gastrointestinal agents  
Gastric acid suppressant 591 5.45 1.89 8363.89 
Laxative 156 1.44 0.76 8606.25 
Antiemetic 36 0.33 0.58 33955.8 
Antacid 22 0.20 0.49 10.5 
Antidiarrheal 11 0.10 1.2 1254.66 
Prokinetic 10 0.09 310.94   
Antiulcerative 5 0.05 3.82 938.25 
Antispasmodic 2 0.02 19.49 3195.49 
Antiflatulent 1 0.01 1.89 5.82 
Endocrine and sexual health 
Antidiabetic 218 2.01 1.12 1705 
Contraceptive 64 0.59 7.54 15040 
Endocrine-metabolic 
agent 
28 0.26 6.5 13200 
Antihypothyroidism 33 0.30 32.77 868.5 
Antiosteoporotic 7 0.06 3.5 158.37 
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Testosterone replacement 5 0.05 18 640.39 
Benign prostatic 
hypertrophy agent 
4 0.04 4.99 2208.86 
Ovulation stimulant 4 0.04 68.55 98175 
Estrogen replacement 3 0.03 26.94 4271.25 
Erectile dysfunction agent 2 0.02 2121.53 7071.56 
Medical Device 
Medical device 118 1.09 3.23 140.23 
Miscellaneous  
Anti-biliary cirrhosis 84 0.78 140 5735.89 
Immunosupressant 12 0.11 32.98 3016.22 
Antineoplastic 10 0.09 3.52 1367.66 
Antirheumatic 7 0.06 3.92 5174.06 
Anesthetic 6 0.06 12 545.11 
Antioxidant 5 0.05 3.95 17.31 
Anti-gout 3 0.03 7.96 541.53 
Anti-renal tubular 
acidosis 
1 0.01 152.62   
Anti-Multiple sclerosis 1 0.01 2691.87   
Anti-relapse 1 0.01 8210.64   
Antiobesity 1 0.01 42.93 81.2 
Uricosuric 1 0.01 59.44 2895 
Ophthalmic 
Ophthalmologic agent 3 0.03 1.39 451.19 
Antiglaucoma 1 0.01 51.05 131.5 
Miotic 1 0.01 40 166.83 
Respiratory 
Bronchodilator 1243 11.47 3.75 8127.5 
Antiasthma 547 5.05 12 1084.66 
Antihistamine 347 3.20 0.64 848.25 
Decongestant 18 0.17 1.56 65.42 
Expectorant 16 0.15 0.98 182.93 
Mucolytic 11 0.10 29.91 752 





CHAPTER 5: DISCUSSION 
 
This chapter provides the study findings, draws conclusions, presents study implications, 
lists limitations for each phase of the study, and provides recommendations for future 
research. 
PART I 
CFTR modulator therapies have revolutionized the treatment of CF by improving 
production, intracellular processing, and/or function of the defective CFTR protein. This 
has resulted in better symptom management and also affected the disease progression. 
Similar to other chronic conditions, adherence to CFTR modulator therapies is essential 
in maximizing the clinical benefit.65 Prior research in CF has mainly focused on 
calculating adherence for pulmonary medications, nebulizers, and multivitamins. 33,66 
CFTR modulator therapies are available in the market since 2012 and still, there is a lack 
of information regarding patient adherence to these medications. The study utilized a 
national specialty pharmacy refill database to assess the utilization of CFTR modulator 
therapies in a CF population including patient adherence.  
The CF Foundation collects data annually from a nationwide network of more 
than 120 CF Foundation accredited centers and provides a data summary in the form of a 
registry report which contributes to clinical trial design, real-world research including 
safety and effectiveness studies of newly approved therapies, and quality improvement. 
The CF Foundation registry report serves as a good reference to understand the 
demographic representation of the AllianceRx Walgreens specialty pharmacy patient 
population used in this study. The 2017 CF Foundation registry reports a total of 29,887 
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patients suffering from CF residing in the US 24 while a total of 4,444 (14.87%) patients 
were utilized for this study. It was observed that the mean age of patients in the study 
(24.41 years) was higher than that reported by the CF Foundation in 2017 (21.7 years). 
The reason for this could be that a higher proportion of adults (64%) were present in the 
AllianceRx Walgreens specialty database in comparison to 53.5% of the adults in the CF 
Foundation registry. In terms of gender distribution, both the CF Foundation registry and 
the study population were similar with higher number of males being present compared 
to females. 
All the patients included in the study had some type of insurance coverage. Public 
health insurance programs are government-funded and provide health care assistance to 
qualifying individuals and their families. These programs include Medicare, Medicaid 
and Children's Health Insurance Program (CHIP). Many states also have CF-specific 
programs such as programs for children with special health care needs (CSHCN 
programs) which provide services such as medically necessary health care, and support 
services including respite care (care provided by others). In most states, families that do 
not qualify for Medicaid may be eligible for this program, while some states require 
enrollment in Medicaid to qualify.67 With so many coverage options provided by the 
government, it was observed that a majority of children/adolescents (54.63%) in the study 
had a primary government health insurance. In adults, a majority of patients (57.46%) 
were on commercial insurance which could have been provided by their employer or 
purchased by the individual.  
Ronan et al. provided a comprehensive list of co-morbidities associated with CF 
which included pulmonary, pancreatic disease, hepatobiliary disease, GIT disorders, 
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kidney disease, genitourinary, bone, coronary artery disease, anxiety, depression and 
others.68 Many of these conditions have been reported by patients in the study. However, 
one of the biggest discrepancies is the difference between prevalence reported in the 
literature and self-reporting frequency of the conditions found in the study. For example, 
anxiety and depression affect 8-33% of patients suffering from CF 24 but the prevalence 
was 1.25% in the study. It is difficult to pin point the reasons for this difference, however, 
it could be attributed to underreporting given that the study relied on patient self-reports. 
There are a number of potential factors that contribute to medication non-
adherence. Understanding problems that patients face that lead to discontinuation, 
missing of medications or suffering from an adverse reaction can help in tailoring 
treatment and guidance for patients, thereby improving adherence. Trimble et al. reported 
that the discontinuation of Kalydeco leads to rapid deterioration of patient's lung function 
and symptoms.69 Our study revealed that the most common reason for discontinuing 
medication was switching which indicates that at least patients were switched to some 
other therapy, which could have helped manage their symptoms. The most frequently 
reported discontinued therapy was Orkambi which was the most utilized therapy by 
patients in the study. Adverse events that were reported by patients during routine 
assessments were also in accordance with the ones reported in the clinical trials of these 
treatments.70–72 
A recent study by Eakin et al. indicated that nonadherence in patients with CF is 
associated with increased hospitalizations and longer length of stays due to pulmonary 
exacerbations and lower baseline lung function.31 However, none of the published studies 
have calculated or reported adherence of patients to CFTR modulator therapies. This 
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study calculated PDC values as a measure of adherence. It is universally accepted that 
PDC values above 0.80 or 80% indicates that the patients are adherent to the treatment. In 
the study, PDC values were calculated for three different time periods to overcome the 
limitations of patients switching medications and also exiting and entering the Walgreens 
system. Except for the PDC value (0.79) in adults on Orkambi, all other PDC values 
across all categorizations exceeded the threshold of 0.80. Symdeko had the highest PDC 
values amongst all medication, which could be due to the availability of refill data for a 
shorter time period (launched in 2018) in comparison to Orkambi and Kalydeco. 
Generally, the availability of refill data for a shorter period of time lowers the chances of 
missed doses resulting in higher PDC values.  
Comparing the PDC values of children/adolescent to adults for Orkambi and 
Symdeko revealed that children/adolescent had a significantly higher PDC value than 
adults. Parental monitoring and timely refilling of medications could be some reasons for 
the higher PDC values. Supporting evidence for adherence to CFTR modulator therapies 
was found in self-reports of patients where majority of them reported not missing any 
doses. Sawicki et al. reported that patients with CF on an average spend 108 minutes per 
day on treatments, which include at least three inhaled and three oral therapies.73 Hence, 
it is understandable that sometimes people forget or are too busy to take the medications 
resulting in missed doses.  
In comparison to previously reported medication adherence of 50% in patients 
with CF, the patients enrolled in this study showed a higher adherence rate. The CF care 
program initiated by AllianceRx Walgreens specialty pharmacy provides timely 
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reminders for refilling medications and provides guidance to patients on a variety of 
topics, which may have contributed to increased adherence in patients.  
 
PART II 
CFTR modulator therapies play an important role in CF management. However, 
with the high acquisition cost (reported as WAC) of Kalydeco, Orkambi and Symdeko 
being $272,886, $311,719 and $292,258, respectively, a significant economic burden is 
placed on both patients and payers. Grosse et al. observed that in 5.8% of patients with 
CF in the US who took ivacaftor in 2016, the drug accounted for 85% of their 
pharmaceutical spending while for lumacaftor/ivacaftor, taken by 17.6% of the CF 
population, accounted for 74% of their total pharmaceutical spending.26 To provide 
further information regarding the economic burden of CFTR modulator therapies, the 
current study aimed to quantify the spending of the AllianceRx Walgreens specialty 
pharmacy and the burden of co-pay on patients related to CFTR modulator therapies. 
Another objective of this study was to provide an estimate of the economic burden of 
medications consumed by patients along with CFTR modulator therapies. There is 
currently no information available on the cost burden of medications for comorbid 
conditions in CF. 
Study results showed an upward trend in the CFTR modulator therapies spending 
by the specialty pharmacy. The reasons for increase in spending could be twofold: 
increased utilization and increased unit cost. Since the methodology accounted for the 
increase in unit cost by utilizing the same WAC to calculate spending across all the years, 
the most probable reason for this increase in spending could be the increase in utilization 
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of CFTR modulator therapies. Over the study period, more patients possibly were 
prescribed these CFTR modulator therapies based on their superior clinical evidence. 
Also, FDA has expanded the indications for the CFTR modulator therapies over time. For 
example, in 2015 Orkambi was approved only in patients above 12 years of age whereas 
in 2018, it was approved for patients above the age of 2 years.74 Over the study period, 
such approvals might have lead a larger population being eligible for the medications 
which could have resulted in increased utilization of CFTR modulator therapies and 
subsequent increase in specialty pharmacy spending. 
The National Institute of Health defines copay as the amount of money that a 
patient with health insurance pays for each healthcare service, such as a visit to the 
doctor, laboratory tests, prescription medicines, and hospital stays.75 The amount of 
copay usually depends on the type of healthcare service and is decided by the insurance 
provider. In theory, copayments were intended to reduce drug expenditure in insured 
population by reducing moral hazard associated with medicines supplied at reduced or 
zero cost. That is, copayments dis-incentivizes the collection of medicines that patients 
do not consume, or which have no role in improving health thus reducing waste. 
However, the co-pays are also said to be a barrier (possibly due to unaffordability) 
resulting in a decrease in use of medications.76  
 Since there is no information available regarding the co-pay for medications in CF 
like the CFTR modulator therapies, this study aimed to provide some insight on the same. 
The range for co-pay across all the years was observed to be extremely broad with the 
lowest copay being $0 and highest being $33,309.57. It can be assumed that the patients 
who might have paid such high co-pays may have received either negligible or no support 
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from their insurance providers. The wide range of co-pays could be attributed to 
differences in insurance and provider characteristics. Also, since the co-pay is decided by 
the insurance providers, no specific trends were observed across all the years. 
 Average co-pay was categorized using insurance characteristics for each CFTR 
modulator therapy. Due to subsidies offered by the government for Medicare, Medicaid, 
and other federal and state funded assistance programs for healthcare, the co-pay of 
patients on such primary health insurances were much lower ($0-$30) than patients on 
commercial health insurance ($25-$310). Additionally, secondary health insurance helps 
in covering a lot of out-of-pocket costs, thus, the secondary co-pay for patients was low 
depending on the type of primary and secondary insurance.  
 Previous literature has associated co-pays with non-adherence especially in 
vulnerable populations (e.g., older people and those on low or fixed incomes) with 
increased sensitivity to adverse health outcomes.76 However, in our study no significant 
differences were observed in adherence of patients were on primary versus those who 
were on primary + secondary insurance even though the co-pay differed for both of these 
populations. This could be because of the chronic nature of CF and the need to consume 
daily medications for symptom management.  
CF is a complex disease affecting various organs in the body. Numerous 
medications are essential in managing various symptoms and complications in patients. 
Grosse et al. estimated the increase in pharmaceutical spending from 2010-2016 but 
didn’t provide an estimation for the therapeutic classes and their individual costs.26 
Cumulatively, these medications can cause a significant economic burden and hence, it 
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was essential to assess the cost of each therapeutic class and how much they contribute to 
the overall burden of CF. 
This was one of the first studies that tried to estimate the utilization and economic 
burden associated with the medications that are being prescribed to CF patients. The 
study revealed that the most common reported medications were anti-infectives, 
respiratory, and electrolyte and dietary supplements. This is in accordance with the 
literature as National Institute of Health has stated that the most serious and common 
complications of CF are problems with the lungs, also known as pulmonary or respiratory 
problems, which may include serious lung infections. Patients with CF also have 
problems maintaining good nutrition, because of the difficulty in absorbing the nutrients 
from food.3  
Due to the variation in dosage strengths and the package sizes, a range was 
estimated for each therapeutic class. Out of the most common therapeutic areas, 
electrolytes and dietary supplements have the broadest range with multivitamins being 
the most expensive ($63,592.75) and iron supplements (0.20) being the least expensive. 
Such a broad range can also be attributed to differences in package sizes. 
This analysis sheds light on different medications that the patients are utilizing. 
The 2017 CF Foundation registry report highlighted the prevalence of mental health 
issues such as depression and anxiety in patients with CF. Analysis of the utilization data 
shows that many patients have reported the use of CNS and mental health products. 
Along with utilization, this study also highlights the economic burden of medications on 
the patients. Since these medications are utilized along with CFTR modulator therapies, 
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the high cost of CFTR modulator therapies along with the cost of other medications can 
cause a substantial economic burden for the patients.  
The 2013 National Health Interview Survey found that to save money, almost 8% 
of US adults (7.8%) did not take their medications as prescribed.77 Many of the patients 
with CF can potentially fall under this category and may have to choose medications 
based on the resources that they have access to. Not taking all the required medications 
can lead to many complications for CF patients and higher healthcare utilization in the 
future.  
 
STUDY IMPLICATIONS  
The present study was one of the first to assess the adherence to CFTR modulator 
therapies in addition to reporting the costs of CFTR modulator therapies and medications 
for comorbid conditions. The study findings have implications to all the stakeholders 
including patients, specialty pharmacy, and payers. 
Implications to the patients 
 The study provided data on discontinuation, missing doses and adverse events 
associated with CFTR modulator therapies. It can assist patients and their caregivers to 
initiate a conversation with their primary care physicians or any patient care coordinators 
regarding issues with medications. Timely intervention can assist patients in being 
adherent to the therapy and decrease complications thereby improving symptom 
management and also quality of life. The study findings can also help patient is the 
understanding their co-pay which can aid the patients and their caregivers in selecting the 





Implications to AllianceRx Walgreens Specialty Pharmacy 
 The study findings support the observation that patients enrolled in the CF 
program at AllianceRx Walgreens specialty pharmacy are adherent to their therapies. The 
reminders and follow ups initiated by the pharmacy are assisting patients in being 
adherent to their therapy.  Understanding the reasons for missing doses and 
discontinuation from patients helps the pharmacy tailor their discussions with patients, 
mostly at an early stage. Additionally, understanding the utilization of other medications 
(other than CFTR modulator therapies) can help the pharmacy in working with patients 
and payers to provide the best possible CF treatment plan. It is important to note that this 
high adherence for CFTR modulator therapies may not be true for retail pharmacy stores 
and/or other specialty pharmacies. 
 
Implications to the payers 
 Patients enrolled in AllianceRx Walgreens specialty pharmacy demonstrated 
higher adherence rates to CFTR regimen. In the long run, adherent patients have been 
shown to have lower complications resulting in lower healthcare utilizations, which helps 
both managed care organizations and payers such as Medicare and Medicaid. 
The payers can also benefit from the findings on average co-pay difference 
between primary and secondary insurances, and commercial and government insurances. 
Since patients can compare the copay for these medications while choosing the plans, the 
payers can use the results from this study to competitively price their co-pay for CFTR 
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modulator therapies which can support the enrollment of higher number of CF patients in 
their plan. Additionally, the study provides payers with the current landscape regarding 
the utilization of the therapeutic class of medications used along with CFTR modulator 
therapies. The payers can tailor plans and provide incentives or discounts to ease the 
burden related to all the medications on the patient.  
 
LIMITATIONS OF THE STUDY 
Both phases of the study have some limitations, and these are discussed in the following 
section. These limitations need to be considered before deriving inferences from the 
reported results.  
Part I  
The limitations associated with any retrospective database are applicable to this 
study. Some of these limitations include retrospective nature of the data, whose quality 
may be limited by systematic or recorder bias, data coding-recoding errors, and 
incomplete data. First, the last refill was used for all patients to describe the patient 
population information. There may be instances where the patient characteristics such as 
residence and co-morbidities could have changed after the last refill and this information 
was not collected as the patients were no longer enrolled with AllianceRx Walgreens 
specialty pharmacy. Hence, there was no way to account for such discrepancy in this 
study. Second, self-reported data was analyzed to identify the responses such as 
discontinuation and adverse events. These responses could be affected by social 
desirability bias as patients may not want to be seen as non-compliant in front of their 
PCC. Additionally, the questions used a recall period of 28 days, which may be subject to 
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recall bias. As self-reported data largely depends on patient’s willingness to share the 
details, patients could have opted out it which could have led to either underreporting of 
some of the responses    
Medication adherence was measured through pharmacy refill data. Although PDC 
is an effective method, it assumes that availability and possession of medication by the 
patient corresponds to the patient actually taking the medication. Thus, adherence 
measurement should be viewed as an estimate, rather than as true results. Medication 
adherence in our study was extremely high. AllianceRx Walgreens specialty pharmacy 
conducts rigorous adherence counseling for its patients and these results may not be 
generalizable to patients using CFTR modulator therapies through another specialty 
pharmacy or retail pharmacies. 
Part II  
  Similar limitations of a retrospective study were also applied to this part. 
Specialty pharmacy spending was calculated using WAC from publicly available Red 
Book. This might not represent the actual spending of the spending pharmacy as price of 
the CFTR modulator therapy would be dependent on the contracts between AllianceRx 
Walgreens specialty pharmacy and the manufacturer. Given the lack of this information 
due to confidentiality agreement, we did not determine the real spending of the specialty 
pharmacy. Also, this result is specific to AllianceRx Walgreens specialty pharmacy and a 
similar trend in the spending can’t be generalized for other specialty pharmacies.  
 Self-reports could be impacted by recall bias and social desirability bias. Patients 
might forget the medication name while reporting or confuse one medication for another 
leading to overreporting or underreporting of medications. There is a possibility that 
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patients might be on some of those medications only for a limited duration and then may 
either switch or discontinue them. There is no way to capture this data. A wide range of 
costs were also calculated from the Red Book based on certain assumptions as brand 
name, package size and daily dosing of the medications were not reported in the data. 
Thus, a single quantifiable value was not obtained for the medications included in the 
data and instead a range was reported. 
 
RECOMMENDATIONS FOR FUTURE RESEARCH  
 This study showed that patients enrolled in AllianceRx Walgreens specialty 
pharmacy are extremely adherent to the CFTR modulator therapies. However, further 
studies should aim to compare the adherence rates of patients enrolled with AllianceRx 
Walgreens specialty pharmacy to patients enrolled in other specialty pharmacies. This 
will help in providing scientific evidence in relation to the CF Program at AllianceRx 
Walgreens specialty pharmacy. Additionally, a longitudinal study using administrative 
claims data could be conducted to observe the healthcare utilization of patients’ adherent 
on CFTR modulator therapies in comparison to those who aren’t. Another area to explore 
could be to quantify the economic burden of different medications used in the treatment 
of CF to a single numeric value using claims and pharmacy records. This will help in 
providing a detailed list of the burden associated with the utilization of different 
therapeutic classes of medications. The systematic review also highlighted that none of 
the studies conducted in the US estimated the caregiver burden associated with CF. 
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Search Strategy for PubMed 
("Cystic Fibrosis"[MESH] OR "Cystic Fibrosis"[tiab] OR "Cystic Fibrosis"[ot] OR 
"Mucoviscidosis”[tiab] OR “Mucoviscidosis"[ot]) 
AND 
(“economics”[MeSH] OR "economics" [Subheading] OR "economic"[tiab] OR 
“economic”[ot] OR "economics"[tiab] OR “economics”[ot] OR "Costs and Cost 
Analysis"[Mesh] OR “cost of illness”[MeSH] OR “cost of illness”[tiab] OR “cost of 
illness”[ot] OR “cost of disease”[tiab] OR “cost of disease”[ot] OR “cost of 
sickness”[tiab] OR “cost of sickness”[ot] OR "Health Care Costs"[Mesh] OR “healthcare 
costs”[tiab] OR “healthcare costs”[ot] OR “healthcare expenditure”[tiab] OR “healthcare 
expenditure”[ot] OR “healthcare utilization”[tiab] OR “health care utilization”[ot] OR 
“health care costs”[tiab] OR “health care costs”[ot] OR “health care expenditure”[tiab] 
OR “health care expenditure”[ot] OR “health care utilization”[tiab] OR “health care 
utilization”[ot] OR “direct service costs”[MeSH] OR “direct service cost”[tiab] OR 
“direct service cost”[ot] OR “direct service costs”[tiab] OR “direct service costs”[ot] OR 
“hospital cost”[tiab] OR “hospital cost”[ot] OR “hospital costs”[MeSH] OR “hospital 
costs”[tiab] OR “hospital costs”[ot] OR “hospitalization cost”[tiab] OR “hospitalization 
cost”[ot] OR “hospitalization costs”[tiab] OR “hospitalization costs”[ot] OR “drug 
cost”[tiab] OR “drug cost”[ot] OR “drug costs”[MeSH] OR “drug costs”[tiab] OR “drug 
costs”[ot] OR "economic burden"[tiab] OR "economic burden"[ot] OR "economic 
burdens"[tiab] OR "economic burdens"[ot] OR “economic impact”[tiab] OR “economic 
impact”[ot] OR “economic impacts”[tiab] OR “economic impacts”[ot] OR “economic 
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cost”[tiab] OR “economic cost”[ot] OR “economic costs”[tiab] OR “economic costs”[ot] 
OR “economic analyses”[tiab] OR “economic analyses”[ot] OR “economic 
analysis”[tiab] OR “economic analysis”[ot] OR “economic consequence”[tiab] OR 
“economic consequence”[ot] OR “economic consequences”[tiab] OR “economic 
consequences”[ot] OR “economic implication”[tiab] OR “economic implication”[ot] OR 
“economic implications”[tiab] OR “economic implications”[ot] OR “medical 
expenditure”[tiab] OR “medical expenditure”[ot] OR “medical expenditures”[tiab] OR 
“medical expenditures”[ot]) 
 
Search Strategy for Scopus 
(INDEXTERMS(“Cystic Fibrosis”) OR TITLE-ABS-KEY(“Cystic Fibrosis”) OR 
TITLE-ABS-KEY(“Mucoviscidosis”)) 
AND 
(INDEXTERMS(“Economics”) OR TITLE-ABS-KEY(“economic*”) OR 
INDEXTERMS(“Costs and cost analysis”) OR 
INDEXTERMS(“cost of illness”) OR TITLE-ABS-KEY(“cost of disease”) OR TITLE-
ABS-KEY(“cost of illness”) OR INDEXTERMS(“health care costs”) OR TITLE-ABS-
KEY(“cost of sickness”) OR TITLE-ABS-KEY(“Claim*”) OR TITLE-ABS-
KEY(“health care expenditure*”) OR TITLE-ABS-KEY(“healthcare expenditure*”) OR 
TITLE-ABS-KEY(“health care utilization”) OR TITLE-ABS-KEY(“healthcare 
utilization”) OR TITLE-ABS-KEY(“health care cost*”) OR TITLE-ABS-
KEY(“healthcare cost*”) OR INDEXTERMS(“direct service costs”) OR TITLE-ABS-
KEY(“direct service cost*”) OR TITLE-ABS-KEY(“hospital cost*”) OR 
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INDEXTERMS(“hospital costs”) OR TITLE-ABS-KEY(“hospitalization cost*”) OR 
TITLE-ABS-KEY(“drug cost*”) OR TITLE-ABS-KEY(“economic burden*”) OR 
TITLE-ABS-KEY(“economic impact*”) OR TITLE-ABS-KEY(“economic cost*”) OR 
TITLE-ABS-KEY(“economic analysis”) OR TITLE-ABS-KEY(“economic analyses”) 
OR TITLE-ABS-KEY(“economic consequence*”) OR TITLE-ABS-KEY(“economic 





Code for objective 1 
/******************** 
Code for demographics 
By Zumi Mehta 
*********************/ 
 
LIBNAME WGD "/folders/myshortcuts/Walgreens_Data"; 
RUN; 
 
FILENAME DMO '/folders/myshortcuts/Walgreens_Data/Clinical_Research_SM6 Data 
- DEIDv1 PDC Calculations 2.xlsx'; 
PROC IMPORT DATAFILE=DMO 
 DBMS=XLSX 
 OUT=WORK.Demo1; 







format Fill_date1 DATE9.; 
IF DRUG_NAME="ORKAMBI 100-125MG GRAN(56=1BX)" THEN 
DRGNAME="ORKAMBI"; 
IF DRUG_NAME="ORKAMBI 100-125MG TAB (112=1BX)" THEN 
DRGNAME="ORKAMBI"; 
IF DRUG_NAME="ORKAMBI 100-125MG TAB(112=1BX)" THEN 
DRGNAME="ORKAMBI"; 
IF DRUG_NAME="ORKAMBI 150-188MG GRAN(56=1BX)" THEN 
DRGNAME="ORKAMBI"; 
IF DRUG_NAME="ORKAMBI 200-125MG TAB (112=1BX)" THEN 
DRGNAME="ORKAMBI"; 
IF DRUG_NAME="ORKAMBI 200-125MG TAB(112=1BX)" THEN 
DRGNAME="ORKAMBI"; 
IF DRUG_NAME="KALYDECO 150MG (14 TAB/CARD)" THEN 
DRGNAME="KALYDECO"; 
IF DRUG_NAME="KALYDECO 150MG TAB" THEN DRGNAME="KALYDECO"; 
IF DRUG_NAME="KALYDECO 150MG TAB (56=1BOX)" THEN 
DRGNAME="KALYDECO"; 
IF DRUG_NAME="KALYDECO ORAL GRAN 50MG (56=1)" THEN 
DRGNAME="KALYDECO"; 




IF DRUG_NAME="SYMDEKO 100-150MG TAB(56=1BOX)" THEN 
DRGNAME="SYMDEKO"; 
IF DRUG_NAME="SYMDEKO 100MG/150MG-150MG TAB" THEN 
DRGNAME="SYMDEKO"; 
run; 


















proc freq data= demo2; 





proc univariate data=demo1; 
var Patient_age ; 
run; 
 
proc freq data=demo1; 




proc freq data=demo1; 
table Primary_Payer_Type ; 
run; 
 










proc freq data= demo2; 
table Primary_Payer_Type; 
where Secondary_Payer_Type=" "; 
run; 
data demo1; 




options missing = ' '; 
data demo2; 
   set demo1; 
   if missing(cats(of _all_)) then delete; 
run; 
 
proc freq data=demo2; 
tables Patient_Gender; 
where .z<fill_date1<'01Jan2016'd;  
run; 
 
proc freq data=demo2; 
tables Patient_Gender; 
where '31Dec2015'd<fill_date1<'01Jan2017'd;  
run; 
 
proc freq data=demo2; 
tables Patient_Gender; 
where '31Dec2016'd<fill_date1<'01Jan2018'd;  
run; 
 
proc freq data=demo2; 
tables Patient_Gender; 
where fill_date1>='01Jan2018'd;  
run; 
 
/*the addition of all of these is not adding up to 4444 so I am trying to create a new 
variable of year*/ 
 
data demo3; 










/*deleting people with no secondary payer*/ 
options missing = ' '; 
data del; 
   set demo2; 




Code for allergy 
By Zumi Mehta 
*********************/ 
 
LIBNAME ALL "/folders/myshortcuts/Walgreens_Data"; 
RUN; 
 
FILENAME ALGg '/folders/myshortcuts/Walgreens_Data/Allergy.xlsx'; 






proc contents data=work.alggg varnum; 
run; 
 




Code for objective 2 
 
/************************* 
CODE TO EXTRACT AND ANALYSE DATA  
REGARDING REASONS AND SIDEFFECTS 
DATE- 3/27/19 
BY: ZUMI MEHTA 
***************************/ 
 





/*IMPORTING THE DATA FILE Clinical_Research_SM6 Data*/ 
 
FILENAME SE1 '/folders/myshortcuts/Walgreens_Data/SR2 _2012-2018 - 
DEIDv1.xlsx'; 
 
PROC IMPORT OUT=WORK.RS1 
DATAFILE=SE1 
 DBMS=XLSX; 
 sheet ="sr2new"; 
 GETNAMES=YES;  
RUN; 
 
PROC contents data=RS1 varnum; 
run; 
 





































































































proc freq data=rs1; 





proc freq data=rs1; 







/*choosing data where we get information only about the discontinued medication*/ 





Code for Objective 3 
 
/************************************* 
Code on 03/12/2018 
 
 110 
PDC CALCULATIONS  
BY: ZUMI MEHTA*/ 
 
 
LIBNAME CDCC "/folders/myshortcuts/Walgreens_Data"; 
RUN; 
 
/*IMPORTING THE DATA FILE Clinical_Research_SM6 Data*/ 
 
FILENAME PG1 '/folders/myshortcuts/Walgreens_Data/Clinical_Research_SM6 Data - 
DEIDv1 PDC Calculations 2.xlsx'; 
 
PROC IMPORT OUT=WORK.CPDC 
DATAFILE=PG1 
 DBMS=XLSX; 
 sheet ="Page1_1"; 
 GETNAMES=YES;  
RUN; 
 






format Fill_date1 DATE9.; 
IF DRUG_NAME="ORKAMBI 100-125MG GRAN(56=1BX)" THEN 
DRGNAME="ORKAMBI"; 
IF DRUG_NAME="ORKAMBI 100-125MG TAB (112=1BX)" THEN 
DRGNAME="ORKAMBI"; 
IF DRUG_NAME="ORKAMBI 100-125MG TAB(112=1BX)" THEN 
DRGNAME="ORKAMBI"; 
IF DRUG_NAME="ORKAMBI 150-188MG GRAN(56=1BX)" THEN 
DRGNAME="ORKAMBI"; 
IF DRUG_NAME="ORKAMBI 200-125MG TAB (112=1BX)" THEN 
DRGNAME="ORKAMBI"; 
IF DRUG_NAME="ORKAMBI 200-125MG TAB(112=1BX)" THEN 
DRGNAME="ORKAMBI"; 
IF DRUG_NAME="KALYDECO 150MG (14 TAB/CARD)" THEN 
DRGNAME="KALYDECO"; 
IF DRUG_NAME="KALYDECO 150MG TAB" THEN DRGNAME="KALYDECO"; 
IF DRUG_NAME="KALYDECO 150MG TAB (56=1BOX)" THEN 
DRGNAME="KALYDECO"; 




IF DRUG_NAME="KALYDECO ORAL GRAN 75MG (56=1)" THEN 
DRGNAME="KALYDECO"; 
IF DRUG_NAME="SYMDEKO 100-150MG TAB(56=1BOX)" THEN 
DRGNAME="SYMDEKO"; 















































/*CREATING A MACRO*/ 
%MACRO MEDAD(lib=, datain=, dataout=, id=, filldt=, daysup=, 
class=, ibendt=., fp=., type=, decpct=2, debug=N); 
%let debug=%upcase(&debug); 
%if (&debug=Y) %then %do; 
 options mprint mtrace macrogen notes linesize=132 ps=58; %end; 
 %else %do; 
 options nonotes nomprint nomacrogen nomtrace nosymbolgen nomlogic 
linesize=132 ps=58; %end; 
%if %sysfunc(exist(&lib..&datain.))=0 %then %do; 
 %put ERROR: DATA SET &datain. DOES NOT EXIST.; 
 %put ERROR- MACRO WILL TERMINATE NOW.; 
 %return; 
 %end; 
%if (&decpct=4) %then %let decpct=0.0001; 
%if (&decpct=3) %then %let decpct=0.001; 
%if (&decpct=2) %then %let decpct=0.01; 
%if (&decpct=1) %then %let decpct=0.1; 
%if (&decpct=) %then %let decpct=1; 
 
/***Step 1***/ 
/***Remove duplicate dispense record***/ 
PROC SORT DATA=&lib..&datain. out=&datain._dedup; BY &id. &class. 
&filldt.; RUN; 
/***Identify first dispense record and last dispense record***/ 
PROC SQL; 
 CREATE TABLE RXCLM 
 AS SELECT &ID., &FILLDT., &CLASS., 
 MIN(&FILLDT.) AS INDEX_DT FORMAT=MMDDYY10., 
 MAX(&FILLDT.) AS LSTRX_DT FORMAT=MMDDYY10., 
 &DAYSUP. 
 FROM &DATAIN._DEDUP 
 GROUP BY &ID., &CLASS. 




/**Create a dataset that contains case with one dispense record only**/ 
DATA ONERX RXCLM1; 
 SET RXCLM END=EOF1; 
 BY &ID. &CLASS.; 
 IF FIRST.&CLASS. AND LAST.&CLASS. THEN OUTPUT ONERX; 





/**Create end date for each dispense record and for the end of study period**/ 
DATA MAXEND; 
 SET RXCLM1; 
 %IF &IBENDT ^=. %THEN %DO; 
 IB_END = (input("&IBENDT.",date9.)) ; /*Cross sectional*/ 
 %END; 
 %ELSE %IF &FP.^=. %THEN %DO; 
 IB_END = INDEX_DT + &FP. -1; 
 %END;/*Longitudinal*/ 
 
 FILL_END_DT = &FILLDT. +&DAYSUP. - 1 ; 
 END_DT=FILL_END_DT; 
 FORMAT END_DT IB_END MMDDYY10.; 
RUN; 
/***Step 4***/ 
/**Create macro for the earliest start date and latest end date**/  
PROC SQL; 
 SELECT MIN(INDEX_DT), MAX(END_DT) 
 INTO :START, :TERM 
 FROM MAXEND; 
QUIT; 
/**Create dummy var to represent days in study period and flag dummy as 1 
if it has drug avaiable**/ 
DATA AD_1; 
 ARRAY FLAG(&START. :&TERM. ); 
 SET MAXEND; 
 BY &ID. &CLASS.; 
 




/* move through the days covered */ 
 DO U=&FILLDT. to FILL_END_DT; 
 FLAG(U)=1; 
 END; 
 DROP I U; 
RUN; 
/***Step 5***/ 








 DO UNTIL (LAST.&CLASS.); 
 SET AD_1; 
 BY &ID. &CLASS.; 
 ARRAY FLAG(&INTRL.) FLAG1-FLAG&INTRL.; 
 ARRAY SUMFLAG(&INTRL.); 
 DO I=1 TO &INTRL.; 
 SUMFLAG(I) = SUM(SUMFLAG(I), FLAG(I)); 
 END; 
 END; 
%IF %UPCASE(&TYPE)=PDC %THEN %DO; 
 DO U=1 TO &INTRL.; 
 IF SUMFLAG(U) GE 1 THEN SUMFLAG(U)=1; ELSE SUMFLAG(U)=0; 
 END; 
%END; 
 DROP I FLAG:; 
RUN; 
/***Step 7***/ 
/**Adjust the end date based off the types of measurements***/ 
DATA &DATAOUT.; 
 SET AD_2; 
 ARRAY TAT(&INTRL.) SUMFLAG1 - SUMFLAG&INTRL.; 
 
 *--Interval based metric; 
 IF IB_END =. THEN &TYPE._1=.; 
 ELSE DO; 
 NUM1=0; 
 ARRAYEND=IB_END - &START. + 1; 
 DO H=1 TO ARRAYEND; 
 NUM1= TAT(H)+ NUM1; 
 END; 
 DENO1= IB_END - INDEX_DT +1; 
 &TYPE._1 = ROUND(MIN((NUM1/DENO1),1), &decpct.); 
 END; 
/**Rx based including last refill**/ 
 NUM2= SUM(OF SUMFLAG1-SUMFLAG&INTRL.); 
 DENO2=FILL_END_DT - INDEX_DT +1; 
 &TYPE._2 = ROUND(MIN((NUM2 /DENO2),1), &decpct.); 
/**Rx based excluding last refill**/ 
 NUM3= SUM(OF SUMFLAG1-SUMFLAG&INTRL.) - (&DAYSUP.); 
 DENO3= &FILLDT. - INDEX_DT; 
 &TYPE._3 = ROUND(MIN((NUM3 /DENO3),1), &decpct.); 
 KEEP &ID. &CLASS. &TYPE.: ; 






%MEDAD (lib=WORK, datain=cpdc, dataout=calpdc, id=PatientID, filldt=Fill_date1, 
daysup=Day_supply, 
class=Drgname, ibendt=31AUG2018, fp=., type=PDC, decpct=2, debug=N); 
%MEDAD (lib=WORK, datain=oney, dataout=oneypdc, id=PatientID, filldt=Fill_date1, 
daysup=Day_supply, 
class=Drgname, ibendt=31AUG2018, fp=., type=PDC, decpct=2, debug=N); 
%MEDAD (lib=WORK, datain=l18, dataout=l18pdc, id=PatientID, filldt=Fill_date1, 
daysup=Day_supply, 
class=Drgname, ibendt=31AUG2018, fp=., type=PDC, decpct=2, debug=N); 
%MEDAD (lib=WORK, datain=g18, dataout=g18pdc, id=PatientID, filldt=Fill_date1, 
daysup=Day_supply, 
class=Drgname, ibendt=31AUG2018, fp=., type=PDC, decpct=2, debug=N); 
%MEDAD (lib=WORK, datain=ol18, dataout=ol18pdc, id=PatientID, filldt=Fill_date1, 
daysup=Day_supply, 
class=Drgname, ibendt=31AUG2018, fp=., type=PDC, decpct=2, debug=N); 
%MEDAD (lib=WORK, datain=og18, dataout=og18pdc, id=PatientID, filldt=Fill_date1, 
daysup=Day_supply, 
class=Drgname, ibendt=31AUG2018, fp=., type=PDC, decpct=2, debug=N); 
%MEDAD (lib=WORK, datain=pcpdc, dataout=pcpdc1, id=PatientID, filldt=Fill_date1, 
daysup=Day_supply, 
class=Drgname, ibendt=31AUG2018, fp=., type=PDC, decpct=2, debug=N); 
 
 proc sql noprint; 
 create table temp as 
 select PATIENTID, count(*) as ct 
 from CalPdc 
 group by PATIENTID; 
 select max(ct) into :_mcount from temp; 
 quit; 
 




proc univariate data=calpdc; 
var PDC_2; 
where drgname= "KALYDEC"; 
run; 
 
proc univariate data=calpdc; 
var PDC_2; 
where drgname= "SYMDEKO"; 
run; 
 




where drgname= "ORKAMBI"; 
run; 
 




proc univariate data=pcpdc1; 
var PDC_2; 
where drgname= "KALYDEC"; 
run; 
 
proc univariate data=pcpdc1; 
var PDC_2; 
where drgname= "SYMDEKO"; 
run; 
 
proc univariate data=pcpdc1; 
var PDC_2; 
where drgname= "ORKAMBI"; 
run; 
 
proc univariate data=oney; 
var Fill_date1; 
Format fill_date1 MMDDYY10.; 
run; 
 








proc univariate data=oneypdc; 
var PDC_2; 
where drgname= "KALYDEC"; 
run; 
 
proc univariate data=oneypdc; 
var PDC_2; 





proc univariate data=oneypdc; 
var PDC_2; 
where drgname= "ORKAMBI"; 
run; 
 




proc univariate data=l18pdc; 
var PDC_2; 
where drgname= "KALYDEC"; 
run; 
 
proc univariate data=l18pdc; 
var PDC_2; 
where drgname= "SYMDEKO"; 
run; 
 
proc univariate data=l18pdc; 
var PDC_2; 
where drgname= "ORKAMBI"; 
run; 
 




proc univariate data=g18pdc; 
var PDC_2; 
where drgname= "KALYDEC"; 
run; 
 
proc univariate data=g18pdc; 
var PDC_2; 
where drgname= "SYMDEKO"; 
run; 
 
proc univariate data=g18pdc; 
var PDC_2; 


















proc univariate data=ol18pdc; 
var PDC_2; 
where drgname= "KALYDEC"; 
run; 
 
proc univariate data=ol18pdc; 
var PDC_2; 
where drgname= "SYMDEKO"; 
run; 
 
proc univariate data=ol18pdc; 
var PDC_2; 
where drgname= "ORKAMBI"; 
run; 
 




proc univariate data=og18pdc; 
var PDC_2; 
where drgname= "KALYDEC"; 
run; 
 
proc univariate data=og18pdc; 
var PDC_2; 
where drgname= "SYMDEKO"; 
run; 
 
proc univariate data=og18pdc; 
var PDC_2; 






















proc freq data=comp noprint; 
tables PatientID/ out=comp1 (Keep=PatientID count where=(count>1)); 
run; 
 







if first.patientid and last.patientid then dup=0; 
else dup=1; 
if dup=1 then delete; 
run; 
 




proc univariate data=compx; 
var PDC_2; 
where drgname= "KALYDEC"; 
run; 
 
proc univariate data=compx; 
var PDC_2; 
where drgname= "SYMDEKO"; 
run; 
 











if first.patientid and last.patientid then dup=0; 
else dup=1; 
if dup=1 then delete; 
run; 
 




proc univariate data=ocompx; 
var PDC_2; 
where drgname= "KALYDEC"; 
run; 
 
proc univariate data=ocompx; 
var PDC_2; 
where drgname= "SYMDEKO"; 
run; 
 
proc univariate data=ocompx; 
var PDC_2; 







if first.patientid and last.patientid then dup=0; 
else dup=1; 
if dup=1 then delete; 
run; 
 








where drgname= "KALYDEC"; 
run; 
 
proc univariate data=gcompx; 
var PDC_2; 
where drgname= "SYMDEKO"; 
run; 
 
proc univariate data=gcompx; 
var PDC_2; 
where drgname= "ORKAMBI"; 
run; 
 








LIBNAME COPAY "/folders/myshortcuts/Walgreens_Data"; 
RUN; 
 
/*IMPORTING THE DATA FILE Clinical_Research_SM6 Data*/ 
 
FILENAME COP '/folders/myshortcuts/Walgreens_Data/Clinical_Research_SM6 Data - 
DEIDv1 PDC Calculations 2.xlsx'; 
 
PROC IMPORT OUT=WORK.COPA 
DATAFILE=COP 
 DBMS=XLSX; 
 sheet ="Page1_1"; 
 GETNAMES=YES;  
RUN; 
 






format Fill_date1 DATE9.; 
 
 122 
IF DRUG_NAME="ORKAMBI 100-125MG GRAN(56=1BX)" THEN 
DRGNAME="ORKAMBI"; 
IF DRUG_NAME="ORKAMBI 100-125MG TAB (112=1BX)" THEN 
DRGNAME="ORKAMBI"; 
IF DRUG_NAME="ORKAMBI 100-125MG TAB(112=1BX)" THEN 
DRGNAME="ORKAMBI"; 
IF DRUG_NAME="ORKAMBI 150-188MG GRAN(56=1BX)" THEN 
DRGNAME="ORKAMBI"; 
IF DRUG_NAME="ORKAMBI 200-125MG TAB (112=1BX)" THEN 
DRGNAME="ORKAMBI"; 
IF DRUG_NAME="ORKAMBI 200-125MG TAB(112=1BX)" THEN 
DRGNAME="ORKAMBI"; 
IF DRUG_NAME="KALYDECO 150MG (14 TAB/CARD)" THEN 
DRGNAME="KALYDECO"; 
IF DRUG_NAME="KALYDECO 150MG TAB" THEN DRGNAME="KALYDECO"; 
IF DRUG_NAME="KALYDECO 150MG TAB (56=1BOX)" THEN 
DRGNAME="KALYDECO"; 
IF DRUG_NAME="KALYDECO ORAL GRAN 50MG (56=1)" THEN 
DRGNAME="KALYDECO"; 
IF DRUG_NAME="KALYDECO ORAL GRAN 75MG (56=1)" THEN 
DRGNAME="KALYDECO"; 
IF DRUG_NAME="SYMDEKO 100-150MG TAB(56=1BOX)" THEN 
DRGNAME="SYMDEKO"; 








PROC UNIVARIATE DATA=COPs; 
VAR PRIMARY_COPAY; 
where drgname= "ORKAMBI"; 
RUN; 
 
PROC UNIVARIATE DATA=COPs; 
VAR PRIMARY_COPAY; 
where drgname= "KALYDEC"; 
RUN; 
 
PROC UNIVARIATE DATA=COPs; 
VAR PRIMARY_COPAY; 





PROC UNIVARIATE DATA=COPs; 
VAR PRIMARY_COPAY; 
where Fill_date1> '31dec2017'd; 
RUN; 
 
PROC UNIVARIATE DATA=COPs; 
VAR PRIMARY_COPAY; 
where drgname= "KALYDEC" and Fill_date1> '31dec2017'd; 
RUN; 
 
PROC UNIVARIATE DATA=COPs; 
VAR PRIMARY_COPAY; 
where drgname= "ORKAMBI" and Fill_date1> '31dec2017'd; 
RUN; 
 
PROC UNIVARIATE DATA=COPs; 
VAR PRIMARY_COPAY; 
where drgname= "SYMDEKO" and Fill_date1> '31dec2017'd; 
RUN; 
 





PROC UNIVARIATE DATA=COPs; 
VAR PRIMARY_COPAY; 
where drgname= "KALYDEC" and '31dec2016'd<Fill_date1<'1jan2018'd; 
RUN; 
 
PROC UNIVARIATE DATA=COPs; 
VAR PRIMARY_COPAY; 
where drgname= "ORKAMBI" and '31dec2016'd<Fill_date1<'1jan2018'd; 
RUN; 
 
PROC UNIVARIATE DATA=COPs; 
VAR PRIMARY_COPAY; 
where drgname= "SYMDEKO" and '31dec2016'd<Fill_date1<'1jan2018'd; 
RUN; 
 









where drgname= "KALYDEC" and '31dec2015'd<Fill_date1<'1jan2017'd; 
RUN; 
 
PROC UNIVARIATE DATA=COPs; 
VAR PRIMARY_COPAY; 
where drgname= "ORKAMBI" and '31dec2015'd<Fill_date1<'1jan2017'd; 
RUN; 
 
PROC UNIVARIATE DATA=COPs; 
VAR PRIMARY_COPAY; 
where drgname= "SYMDEKO" and '31dec2015'd<Fill_date1<'1jan2017'd; 
RUN; 
 





PROC UNIVARIATE DATA=COPs; 
VAR PRIMARY_COPAY; 
where drgname= "KALYDEC" and '31dec2014'd<Fill_date1<'1jan2016'd; 
RUN; 
 
PROC UNIVARIATE DATA=COPs; 
VAR PRIMARY_COPAY; 
where drgname= "ORKAMBI" and '31dec2014'd<Fill_date1<'1jan2016'd; 
RUN; 
 
PROC UNIVARIATE DATA=COPs; 
VAR PRIMARY_COPAY; 





where Secondary_Payer_Type=" "; 
run; 
 









where drgname= "ORKAMBI" and Primary_Payer_Type="Commercial"; 
RUN; 
 
PROC UNIVARIATE DATA=onlyp; 
VAR PRIMARY_COPAY; 
where drgname= "KALYDEC" and Primary_Payer_Type="Commercial"; 
RUN; 
 
PROC UNIVARIATE DATA=onlyp; 
VAR PRIMARY_COPAY; 
where drgname= "SYMDEKO" and Primary_Payer_Type="Commercial"; 
RUN; 
 
PROC UNIVARIATE DATA=onlyp; 
VAR PRIMARY_COPAY; 
where Fill_date1> '31dec2017'd and Primary_Payer_Type="Commercial"; 
RUN; 
 
PROC UNIVARIATE DATA=onlyp; 
VAR PRIMARY_COPAY; 




PROC UNIVARIATE DATA=onlyp; 
VAR PRIMARY_COPAY; 




PROC UNIVARIATE DATA=onlyp; 
VAR PRIMARY_COPAY; 




PROC UNIVARIATE DATA=onlyp; 
VAR PRIMARY_COPAY; 
where '31dec2016'd<Fill_date1<'1jan2018'd and Primary_Payer_Type="Commercial";  
RUN; 
 
PROC UNIVARIATE DATA=onlyp; 
VAR PRIMARY_COPAY; 






PROC UNIVARIATE DATA=onlyp; 
VAR PRIMARY_COPAY; 




PROC UNIVARIATE DATA=onlyp; 
VAR PRIMARY_COPAY; 




PROC UNIVARIATE DATA=onlyp; 
VAR PRIMARY_COPAY; 
where '31dec2015'd<Fill_date1<'1jan2017'd and Primary_Payer_Type="Commercial";  
RUN; 
 
PROC UNIVARIATE DATA=onlyp; 
VAR PRIMARY_COPAY; 




PROC UNIVARIATE DATA=onlyp; 
VAR PRIMARY_COPAY; 




PROC UNIVARIATE DATA=onlyp; 
VAR PRIMARY_COPAY; 




PROC UNIVARIATE DATA=onlyp; 
VAR PRIMARY_COPAY; 
where '31dec2014'd<Fill_date1<'1jan2016'd and Primary_Payer_Type="Commercial"; 
RUN; 
 
PROC UNIVARIATE DATA=onlyp; 
VAR PRIMARY_COPAY; 






PROC UNIVARIATE DATA=onlyp; 
VAR PRIMARY_COPAY; 




PROC UNIVARIATE DATA=onlyp; 
VAR PRIMARY_COPAY; 
















PROC UNIVARIATE DATA=psCOPs; 
VAR PRIMARY_COPAY; 
where drgname= "KALYDEC"; 
RUN; 
 
PROC UNIVARIATE DATA=psCOPs; 
VAR PRIMARY_COPAY; 
where drgname= "ORKAMBI"; 
RUN; 
 
PROC UNIVARIATE DATA=psCOPs; 
VAR PRIMARY_COPAY; 
where drgname= "SYMDEKO"; 
RUN; 
 
PROC UNIVARIATE DATA=psCOPs; 
VAR PRIMARY_COPAY; 
where Fill_date1> '31dec2017'd; 
RUN; 
 




where drgname= "KALYDEC" and Fill_date1> '31dec2017'd; 
RUN; 
 
PROC UNIVARIATE DATA=psCOPs; 
VAR PRIMARY_COPAY; 
where drgname= "ORKAMBI" and Fill_date1> '31dec2017'd; 
RUN; 
 
PROC UNIVARIATE DATA=psCOPs; 
VAR PRIMARY_COPAY; 
where drgname= "SYMDEKO" and Fill_date1> '31dec2017'd; 
RUN; 
 





PROC UNIVARIATE DATA=psCOPs; 
VAR PRIMARY_COPAY; 
where drgname= "KALYDEC" and '31dec2016'd<Fill_date1<'1jan2018'd; 
RUN; 
 
PROC UNIVARIATE DATA=psCOPs; 
VAR PRIMARY_COPAY; 
where drgname= "ORKAMBI" and '31dec2016'd<Fill_date1<'1jan2018'd; 
RUN; 
 
PROC UNIVARIATE DATA=psCOPs; 
VAR PRIMARY_COPAY; 
where drgname= "SYMDEKO" and '31dec2016'd<Fill_date1<'1jan2018'd; 
RUN; 
 





PROC UNIVARIATE DATA=psCOPs; 
VAR PRIMARY_COPAY; 
where drgname= "KALYDEC" and '31dec2015'd<Fill_date1<'1jan2017'd; 
RUN; 
 




where drgname= "ORKAMBI" and '31dec2015'd<Fill_date1<'1jan2017'd; 
RUN; 
 
PROC UNIVARIATE DATA=psCOPs; 
VAR PRIMARY_COPAY; 
where drgname= "SYMDEKO" and '31dec2015'd<Fill_date1<'1jan2017'd; 
RUN; 
 





PROC UNIVARIATE DATA=psCOPs; 
VAR PRIMARY_COPAY; 
where drgname= "KALYDEC" and '31dec2014'd<Fill_date1<'1jan2016'd; 
RUN; 
 
PROC UNIVARIATE DATA=psCOPs; 
VAR PRIMARY_COPAY; 
where drgname= "ORKAMBI" and '31dec2014'd<Fill_date1<'1jan2016'd; 
RUN; 
 
PROC UNIVARIATE DATA=psCOPs; 
VAR PRIMARY_COPAY; 









PROC UNIVARIATE DATA=psCOPs; 
VAR SECONDARY_COPAY; 
where drgname= "KALYDEC"; 
RUN; 
 
PROC UNIVARIATE DATA=psCOPs; 
VAR SECONDARY_COPAY; 
where drgname= "ORKAMBI"; 
RUN; 
 




where drgname= "SYMDEKO"; 
RUN; 
 
PROC UNIVARIATE DATA=psCOPs; 
VAR SECONDARY_COPAY; 
where Fill_date1> '31dec2017'd; 
RUN; 
 
PROC UNIVARIATE DATA=psCOPs; 
VAR SECONDARY_COPAY; 
where drgname= "KALYDEC" and Fill_date1> '31dec2017'd; 
RUN; 
 
PROC UNIVARIATE DATA=psCOPs; 
VAR SECONDARY_COPAY; 
where drgname= "ORKAMBI" and Fill_date1> '31dec2017'd; 
RUN; 
 
PROC UNIVARIATE DATA=psCOPs; 
VAR SECONDARY_COPAY; 
where drgname= "SYMDEKO" and Fill_date1> '31dec2017'd; 
RUN; 
 





PROC UNIVARIATE DATA=psCOPs; 
VAR SECONDARY_COPAY; 
where drgname= "KALYDEC" and '31dec2016'd<Fill_date1<'1jan2018'd; 
RUN; 
 
PROC UNIVARIATE DATA=psCOPs; 
VAR SECONDARY_COPAY; 
where drgname= "ORKAMBI" and '31dec2016'd<Fill_date1<'1jan2018'd; 
RUN; 
 
PROC UNIVARIATE DATA=psCOPs; 
VAR SECONDARY_COPAY; 
where drgname= "SYMDEKO" and '31dec2016'd<Fill_date1<'1jan2018'd; 
RUN; 
 







PROC UNIVARIATE DATA=psCOPs; 
VAR SECONDARY_COPAY; 
where drgname= "KALYDEC" and '31dec2015'd<Fill_date1<'1jan2017'd; 
RUN; 
 
PROC UNIVARIATE DATA=psCOPs; 
VAR SECONDARY_COPAY; 
where drgname= "ORKAMBI" and '31dec2015'd<Fill_date1<'1jan2017'd; 
RUN; 
 
PROC UNIVARIATE DATA=psCOPs; 
VAR SECONDARY_COPAY; 
where drgname= "SYMDEKO" and '31dec2015'd<Fill_date1<'1jan2017'd; 
RUN; 
 





PROC UNIVARIATE DATA=psCOPs; 
VAR SECONDARY_COPAY; 
where drgname= "KALYDEC" and '31dec2014'd<Fill_date1<'1jan2016'd; 
RUN; 
 
PROC UNIVARIATE DATA=psCOPs; 
VAR SECONDARY_COPAY; 
where drgname= "ORKAMBI" and '31dec2014'd<Fill_date1<'1jan2016'd; 
RUN; 
 
PROC UNIVARIATE DATA=psCOPs; 
VAR SECONDARY_COPAY; 





List of all co-morbidities 
Disease  Frequency (n) Percent (%) 
Endocrine, nutritional and metabolic diseases, and 
immunity disorders, diseases of the blood and blood-
forming organs   
4770 56.83 
Diseases of the respiratory system  1143 13.62 
Infectious and parasitic diseases  563 6.71 
Diseases of the digestive system  496 5.91 
Symptoms, signs, and ill-defined conditions  375 4.47 
Diseases of the nervous system and sense organs  252 3.00 
Congenital anomalies  187 2.23 
Diseases of the genitourinary system  111 1.32 
Diseases of the skin and subcutaneous tissue  111 1.32 
Mental disorders  105 1.25 
Diseases of the musculoskeletal system and 
connective tissue  
75 0.89 
Diseases of the circulatory system  71 0.85 
Injury and poisoning  59 0.70 
Certain conditions originating in the perinatal period  41 0.49 
Neoplasms  18 0.21 









List of all reported allergies 
Allergy Frequency (n) Percent (%) 
No Known Drug Allergy 3016 66.07 
Allergy History Not Known 365 8 
Sulfa Antibiotics 219 4.8 
Penicillins 183 4.01 
No Known Environmental Allergy 137 3 
Sulfonamide Derivatives 111 2.43 
Cephalosporins 64 1.4 
No Known Food Allergy 47 1.03 
Vancomycin 38 0.83 
Latex 34 0.74 
Adhesive 32 0.7 
Hydrocodone 28 0.61 
Peanut-containing Drug Products 26 0.57 
Sulfa Drugs Cross Reactors 23 0.5 
Morphine and Related 18 0.39 
Quinolones 18 0.39 
Streptokinases 13 0.28 
Gluten 11 0.24 
Rifamycins 11 0.24 
Shellfish-derived Products 11 0.24 
Eggs or Egg-derived Products 10 0.22 
Macrolides and Ketolides 10 0.22 
Plastic tape 10 0.22 
Spironolactone 8 0.18 
Nsaids 7 0.15 
Paper tape 7 0.15 
Aminoglycosides 6 0.13 
Milk-related Compounds 6 0.13 
No Known Latex Allergy 6 0.13 
Iodides 5 0.11 
Lactose Intolerance (GI) 5 0.11 
Red Dye 5 0.11 
Clindamycin/Lincomycin 4 0.09 
Soybean-containing Drug Products 4 0.09 
 
 134 
Antihistamines 3 0.07 
Egg 3 0.07 
Fish-derived Products 3 0.07 
Iodinated Diagnostic Agents 3 0.07 
Salicylates 3 0.07 
Tetracyclines & Related 3 0.07 
Allopurinol 2 0.04 
Aztreonam 2 0.04 
Barbiturates 2 0.04 
Corn-containing Products 2 0.04 
Nitrofuran Derivatives 2 0.04 
Silver 2 0.04 
Statins 2 0.04 
Sulfites 2 0.04 
Uncoded Nonscreenable Allergen 2 0.04 
Chlorpheniramine-type 1 0.02 
Loratadine-type 1 0.02 
ACE Inhibitors 1 0.02 
Acetaminophen 1 0.02 
Alpha Blocker Quinazolines 1 0.02 
Aminoquinolines 1 0.02 
Beta Adrenergic Blockers 1 0.02 
Blue Dyes (Parenteral) 1 0.02 
Clavulanic Acid 1 0.02 
Corticosteroids 1 0.02 
Dienestrol 1 0.02 
Ethylenediamine 1 0.02 
Glutethimides 1 0.02 
Green Dyes 1 0.02 
Guaifenesin & Derivatives 1 0.02 
IV Dye 1 0.02 
Immune Globulins 1 0.02 
Insulins 1 0.02 
Janumet 1 0.02 
Nuts 1 0.02 
PABA Derivatives 1 0.02 
Peanuts 1 0.02 
Pork-derived Products 1 0.02 
Strawberries 1 0.02 
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Streptomycin 1 0.02 
Succinamides 1 0.02 
Tegaderm 1 0.02 
Tetanus Toxoids 1 0.02 
Thimerosal 1 0.02 
Tramadol 1 0.02 
Trimethoprim 1 0.02 
 
